Document:

EX-10.8

 Exhibit 10.8 

LICENSE AGREEMENT 
 THIS
LICENSE AGREEMENT made and entered into this 21st day of September, 2004 (“EFFECTIVE DATE”), by and between DUKE UNIVERSITY, a nonprofit educational and research institution organized
under the laws of North Carolina (“DUKE”), having its principal office at Durham, North Carolina 27708, and Cellective Therapeutics, Inc., a corporation organized under the laws of Delaware (“COMPANY”), with its corporate
headquarters and principal office at 4819 Emperor Boulevard, Suite 400, Durham, North Carolina 27703. 
 WHEREAS, DUKE owns certain DUKE
PATENT RIGHTS (as hereinafter defined) relating to the following inventions submitted to the DUKE Office of Science and Technology (collectively, the “INVENTIONS”, and individually, “INVENTION”): 

 

	 	•	 	 [***]; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; and 

WHEREAS, DUKE has the right to grant licenses under said DUKE PATENT RIGHTS; and 

WHEREAS, DUKE desires to have the DUKE PATENT RIGHTS developed and commercialized to benefit the public and is willing to grant licenses to
each hereunder; and 
 WHEREAS, COMPANY desires to obtain licenses under DUKE PATENT RIGHTS upon the terms and conditions hereinafter set
forth; and 
 WHEREAS, certain of the INVENTIONS were made with U.S. Government support and, notwithstanding anything to the contrary in
this AGREEMENT, the U.S. Government has certain rights in such INVENTIONS under 37 C.F.R. §§ 401 et seq. 
 NOW THEREFORE, in
consideration of the premises and the mutual covenants contained herein, the parties hereto agree as follows: 
 ARTICLE 1 - DEFINITIONS 

For the purposes of this AGREEMENT, and solely for that purpose, the terms and phrases set forth below and elsewhere in this AGREEMENT in
capital letters shall be defined as follows: 
  

	 	1.01	 “AFFILIATE” shall mean any corporation or non-corporate
entity which controls, is controlled by or is under the common control with a party hereto. A corporation or a non-corporate entity, as applicable, shall be regarded as in control of another corporation if it
owns or directly or indirectly controls at least fifty percent (50%) of the voting stock of the other corporation, or in the absence of ownership of at least fifty percent (50%) of the voting stock of a corporation, or in the case of a non-corporate entity, if it possesses directly or indirectly, the power to direct or cause the direction of the management and policies of such corporation or non-corporate
entity, as applicable. 

  
 1 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	1.02	 “AGREEMENT” shall mean this License Agreement, including all attached schedules and appendices, which
are incorporated herein by reference. 

  

	 	1.03	 “BLA” shall mean a biologics license application filed in accordance with 42 U.S.C. § 262, as
amended. 

  

	 	1.04	 “CONFIDENTIAL INFORMATION” shall mean any and all confidential information of one party disclosed to
the other party including, without limitation, (i) all product specifications, data, test results, formulae, compositions, processes, technology, designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current,
and planned research and development, computer software and programs (including object code and source code), computer software and database technologies, systems, structures, and architectures, historical financial statements, financial projections
and budgets, historical and projected sales, capital spending budgets and plans, the names and backgrounds of key personnel, personnel training and techniques and materials, client lists, customer lists, current and anticipated customer
requirements, price lists, cost information, market studies, business plans, however documented, and (ii) all notes, analyses, compilations, studies, summaries, and other material containing or based, in whole or in part, on any information
included in the foregoing, and any other information, however documented, that is proprietary to a party. 

  

	 	1.05	 “DUKE MATERIALS” shall mean biological and other materials whose composition of matter and/or use are
covered by DUKE PATENT RIGHTS. 

  

	 	1.06	 “DUKE PATENT RIGHTS” shall mean collectively (i) the patent applications listed in APPENDIX A,
together with all divisions, continuations, continuations-in-part, and foreign counterparts thereof (such patent applications hereinafter collectively referred to as
“DUKE PATENT APPLICATIONS”) and (ii) re-examinations, reissues, substitutions, or extensions thereof and patents issuing therefrom in the United States and
non-U.S. jurisdictions (collectively “DUKE PATENTS”). Notwithstanding the foregoing or anything else to the contrary in this AGREEMENT, DUKE PATENT RIGHTS shall not include those patents and/or
patent applications which, during the term of this AGREEMENT, cease to be DUKE PATENT RIGHTS pursuant to Section 6.01 or Section 6.02. It is understood and agreed that subject matter that is PATENTABLY DISTINCT (defined below) from the
subject matter described within the DUKE PATENT APPLICATIONS is not within the scope of the DUKE PATENT RIGHTS even though that PATENTABLY DISTINCT subject matter may fall within the scope of one or more claims of said DUKE PATENT APPLICATIONS.
PATENTABLY DISTINCT improvements relating to the subject matter of DUKE PATENT APPLICATIONS shall not be considered DUKE PATENT RIGHTS. As used herein, “PATENTABLY DISTINCT” subject matter is subject matter that is novel and unobvious over
subject matter described within said DUKE PATENT APPLICATIONS. 

  
 2 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	1.07	 “DUKE PATENT RIGHTS EXPENSES” shall mean all patent-related expenses (including, but not limited to,
filing fees, maintenance fees, and reasonable fees and expenses of patent counsel) incurred in connection with the DUKE PATENT RIGHTS, including but not limited to all reasonable expenses incurred in connection with the assembly and copying of files
for transfer to and from (as the case may be) COMPANY’s legal counsel in connection with COMPANY’s assuming responsibility for DUKE PATENT RIGHTS or transferring some of all of that responsibility back to DUKE (as the case may be) pursuant
to Section 6.01(a) and/or Section 6.02(b). 

  

	 	1.08	 “FIELD OF USE” shall mean any and all uses. 

 

	 	1.09	 “INVENTOR” means any individual who is identified as an inventor on one or more of the DUKE PATENT
RIGHTS (in accordance with applicable patent law) and whose contribution as an inventor to such DUKE PATENT RIGHTS was made as result of his/her association with DUKE such that the individual is obligated to assign his/her rights in such DUKE PATENT
RIGHTS to DUKE. 

  

	 	1.10	 “KNOW-HOW” shall mean any research information, technical
information, technical data or other confidential information not in the public domain generated at DUKE prior to the EFFECTIVE DATE by one or more of the appertaining INVENTORS of one or more subject DUKE PATENT RIGHTS which relate to and are
necessary for the practice of the subject DUKE PATENT RIGHTS and are not claimed in the DUKE PATENT RIGHTS. Notwithstanding the foregoing and for avoidance of doubt, KNOW-HOW shall include all unpatented and
unpatentable inventions, technology, cell lines, biological materials, compounds, probes, sequences, methodology and uses generated at DUKE by one of the appertaining INVENTORS of one or more subject DUKE PATENT RIGHTS prior to the EFFECTIVE DATE
and which relate to and are necessary for the practice of the subject DUKE PATENT RIGHTS, but shall not include any inventions, technology, cell lines, biological materials, compounds, probes, sequences, or methods or any uses thereof
(i) which are patented, or (ii) which are the subject(s) of one or more pending patent applications, or (iii) which are patentable but unpatented unless DUKE has provided COMPANY with written notification that it has elected not to
pursue patent protection, in which case such items shall be deemed to fall within the scope of KNOW-HOW. Further, notwithstanding the foregoing and for the avoidance of doubt,
KNOW-HOW shall not include any such inventions, technology, cell lines, biological materials, compounds, probes, sequences, or methods or any uses thereof which DUKE cannot provide to COMPANY due to
(y) other legal obligations of DUKE pursuant to sponsored research, clinical research, material transfer, license, option to license, confidentiality, or other agreements and/or (z) circumstances relating to third-party patent rights.

  
 3 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	1.11	 “LICENSED PROCESS” shall mean any process which is covered in whole or in part by a claim contained
in the DUKE PATENT RIGHTS and/or which is derived from use of one or more INVENTIONS claimed in the DUKE PATENT RIGHTS. For the purpose of this AGREEMENT, LICENSED PROCESSES shall be deemed to fall within the scope of LICENSED PRODUCTS
notwithstanding such process is not literally a “product”. 

  

	 	1.12	 “LICENSED PRODUCT” shall mean any product or part thereof which: 

 

	 	(a)	 is covered in whole or in part by any claim contained in the DUKE PATENT RIGHTS in the country in which any
such product or part thereof is made, used or sold; and/or 

  

	 	(b)	 is manufactured by using a process or is employed to practice a process which is covered in whole or in part by
a claim contained in the DUKE PATENT RIGHTS in the country in which any LICENSED PROCESS is used or in which such product or part thereof is used or sold; and/or 

 

	 	(c)	 in its intended use, practices, incorporates, or otherwise utilizes, in whole, or in part, a claim contained in
the DUKE PATENT RIGHTS in the country in which any such product or part thereof is made, used, or sold; and/or 

  

	 	(d)	 is derived from use of one or more INVENTIONS claimed in the DUKE PATENT RIGHTS. 

For avoidance of doubt, a LICENSED PRODUCT shall not include any product for which DUKE MATERIALS or DUKE PATENT RIGHTS are used in connection
with the research, development or testing of such product, but into which no DUKE MATERIALS are incorporated unless the manufacture, use or sale of such product would, without the LICENSE granted herein, infringe the DUKE PATENT RIGHTS. 

 

	 	1.13	 “LICENSED SERVICE” shall mean any service provided by COMPANY (and/or SUBLICENSEES, as the case may
be) to a THIRD PARTY which utilizes one or more LICENSED PRODUCTS and/or LICENSED PROCESSES. 

  

	 	1.14	 “LICENSES” shall mean collectively, the DUKE PATENT RIGHTS LICENSE (as defined in Section 2.01
below) and KNOW-HOW LICENSE (as defined in Section 2.02 below). 

  

	 	1.15	 “NDA” shall mean a new drug application filed in accordance with 21 U.S.C. § 355, as amended.

  

	 	1.16	 “NET SALES” shall mean: 

 

	 	(a)	 in the case of LICENSED PRODUCTS, revenue received by COMPANY (and/or SUBLICENSEES, as the case may be) from
sale and/or lease of the subject LICENSED PRODUCTS to a THIRD PARTY; and 

  
 4 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(b)	 in the case of LICENSED SERVICES, revenue received by COMPANY (and/or SUBLICENSEES, as the case may be) for
provision of the subject LICENSED SERVICE to a THIRD PARTY; and 

  

	 	(c)	 in the case that one or more LICENSED PRODUCTS and/or LICENSED SERVICES are sold in a combination package or
kit containing other active products or processes or services, then NET SALES for purposes of determining DUKE RUNNING ROYALTIES due to DUKE on the combination package or kit in accordance with Section 3.01(b) will be calculated using one of
the following methods: 

 (i) By multiplying the net sales of the combination by the fraction A/A+B, where A is the gross
selling price, during the royalty-paying period in question, of the subject LICENSED PRODUCT and/or LICENSED SERVICE sold separately, and B is the gross selling price during the royalty period in question, of the other active products, processes or
services sold separately; or 
 (ii) If no separate sales are made of the subject LICENSED PRODUCT and/or LICENSED SERVICE or of the other
active agents or processes in such combination package during the royalty-paying period in question, NET SALES will be calculated by dividing the price of the combination by the number of active functions performed by the combination sold and then
multiplying that figure by the number of active functions performed by the LICENSED PRODUCT and/or LICENSED SERVICE in that combination where such combination contains active agents or processes other than those licensed under this AGREEMENT. For
avoidance of doubt, the number of such active functions shall be determined in good faith by COMPANY and approved by DUKE, such approval not to be unreasonably withheld; 

and each of (a) (b), and (c) above shall be less the sum of the following: 

 

	 	(w)	 discounts allowed in amounts customary in the trade; 

 

	 	(x)	 sales, tariff duties and/or use taxes directly imposed and with reference to particular sales;

  

	 	(y)	 outbound transportation prepaid or allowed; and 

 

	 	(z)	 amounts allowed or credited on returns. 

No deductions to NET SALES shall be made for commissions paid to individuals whether they are associated with independent sales agencies or
regularly employed by COMPANY (and/or SUBLICENSEES, as the case may be) and on its payroll, or for cost of collections. LICENSED PRODUCTS shall be considered “sold” when the consideration for provision thereof is received by COMPANY
(and/or 

  
 5 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
SUBLICENSEES, as the case may be). LICENSED PRODUCTS and LICENSED SERVICES used by COMPANY (and/or SUBLICENSEES, as the case may be) for its own use in the FIELD OF USE (and not in connection
with the sale to THIRD PARTIES) shall be considered to be “NET SALES” for purposes of computing royalty obligations, except to the extent that such LICENSED PRODUCTS and/or LICENSED SERVICES are used for clinical field trials or for
COMPANY’s own internal non-commercial research (and/or SUBLICENSEES, as the case may be). For avoidance of doubt, NET SALES shall not include royalties, license fees, milestone payments or other
consideration received from SUBLICENSEES in consideration of SUBLICENSES. For purposes of illustration and clarification of the preceding sentence, if a SUBLICENSEE has agreed to pay running royalties to COMPANY at a rate of [***] ([***]) of [***]
and collects $[***] in [***] in a particular royalty reporting period, then the amount owed to DUKE hereunder as DUKE RUNNING ROYALTIES in respect of such NET SALES by such SUBLICENSEE shall be [***] ([***]) of $[***] or $[***] and none of such
running royalties payable by such SUBLICENSEE to COMPANY shall be included in NET SALES. 
  

	 	1.17	 “SUBLICENSE” and “SUBLICENSE AGREEMENT” shall mean, and include without limitation, any
relationship/agreement in which a THIRD PARTY gains any rights—temporary or otherwise—to any of the rights granted by DUKE to COMPANY under this AGREEMENT (including, but not limited to, COMPANY AFFILIATES, assignee(s), licensee(s),
sublicensee(s), marketing partner(s) and the like, hereinafter, such THIRD PARTIES referred as “SUBLICENSEES”), including, but not limited to those granted via options, rights of first refusal, material transfer agreements, or sublicenses
(implied or expressed). 

  

	 	1.18	 “THIRD PARTY” means any individual or other entity other than DUKE and/or COMPANY.

  

	 	1.19	 Where appropriate, words denoting a singular number only shall include the plural and vice versa.

  

	 	1.20	 Certain other defined terms shall have the meanings given them elsewhere in this AGREEMENT.

 ARTICLE 2 - LICENSE 
  

	 	2.01	 DUKE hereby grants to COMPANY and COMPANY hereby accepts from DUKE, subject to the terms and conditions of this
AGREEMENT, an exclusive, world-wide license to DUKE’s rights in the DUKE PATENT RIGHTS to use and practice the DUKE PATENT RIGHTS to make, have made, use, manufacture, have manufactured, market, import, export, offer for sale and sell LICENSED
PRODUCTS with applications in the FIELD OF USE, and LICENSED SERVICES for use in the FIELD OF USE (the “DUKE PATENT RIGHTS LICENSE”) until the end of the term for which the DUKE PATENT RIGHTS collectively are granted unless this AGREEMENT
shall be sooner terminated according to the terms hereinafter provided. 

  
 6 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	2.02	 DUKE hereby grants to COMPANY and COMPANY hereby accepts from DUKE, subject to the terms and conditions of this
AGREEMENT, a non-exclusive license to DUKE’s rights in the KNOW-HOW to use and practice the KNOW-HOW to make, have made,
use, manufacture, have manufactured, market, import, export, offer for sale and sell LICENSED PRODUCTS with applications in the FIELD OF USE, and LICENSED SERVICES for use in the FIELD OF USE (the
“KNOW-HOW LICENSE”) until the end of the term for which the DUKE PATENT RIGHTS collectively are granted unless this AGREEMENT shall be sooner terminated according to the terms hereinafter provided.
The KNOW-HOW LICENSE shall be sublicenseable by LICENSEE, but only in connection with the grant by COMPANY of a SUBLICENSE under all or some of the appertaining DUKE PATENT RIGHTS in the FIELD OF USE. For
avoidance of doubt, it is understood and acknowledged that nothing in this AGREEMENT shall be construed to restrict DUKE from using the KNOW-HOW as it sees fit (which shall include, but shall not be limited
to, the transferring of KNOW-HOW to any THIRD PARTY). 

  

	 	2.03	 Notwithstanding anything to the contrary in this AGREEMENT, it is understood and agreed that DUKE encourages
COMPANY (and/or SUBLICENSEE(S), as the case may be) to secure rights under any THIRD PARTY intellectual property rights required to practice the technology and/or to exercise any and all of the rights practiced or exercised by COMPANY or such
SUBLICENSEE(S) (as the case may be) pursuant to Sections 2.01 and 2.02, and that DUKE shall have no responsibility in securing any such rights. Further, if COMPANY (and/or any SUBLICENSEE, as the case may be) secures any such rights to THIRD PARTY
intellectual property rights in order to practice the technology and/or to exercise any or all of the rights granted under Sections 2.01 and 2.02, then COMPANY (and/or such SUBLICENSEE, as the case may be) shall use its best efforts to secure from
any such THIRD PARTY a covenant not to sue DUKE, or any of its faculty, students, employees or agents, for any research and development efforts conducted at DUKE that resulted in the creation of any of the INVENTIONS and/or KNOW-HOW and/or any licensing thereof, and any intellectual property or other rights arising therefrom, including, but not limited to, DUKE PATENT RIGHTS. 

 

	 	2.04	 The LICENSES granted hereunder shall be sublicenseable subject to the terms and conditions set forth in this
AGREEMENT (including but not limited to those set forth in Sections 2.02, 2.04, 2.05, and 2.06). All SUBLICENSES shall be subject to the terms and conditions of this AGREEMENT, shall be no less favorable to or protective of DUKE than this AGREEMENT
except as expressly stated in this AGREEMENT, and shall not be further sublicenseable without the express written approval of DUKE, such approval not to be unreasonably withheld. COMPANY shall use commercially reasonable efforts to enforce the terms
of the SUBLICENSE AGREEMENTS. COMPANY further agrees to provide DUKE with a copy of each SUBLICENSE AGREEMENT within [***] ([***]) [***] of its execution by all parties involved. 

  
 7 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	2.05	 Notwithstanding anything to the contrary in this AGREEMENT, DUKE hereby retains the following rights pertaining
to the INVENTIONS, DUKE PATENT RIGHTS, and DUKE MATERIALS (such rights being retained by Duke without payment of royalties or other fees): 

  

	 	(a)	 to use and practice for non-commercial, academic research, teaching,
clinical, and educational purposes at DUKE and its affiliated research, teaching, clinical, or educational functions; 

  

	 	(b)	 subject to the prior written approval of COMPANY, such approval not to be unreasonably withheld, to provide
such DUKE PATENT RIGHTS (including, but not limited to, DUKE MATERIALS) to THIRD PARTIES (including, but not limited to, governmental laboratories, institutions of higher learning and research, and commercial entities), but without the right to
sublicense such rights, to be used for research purposes only in research funded by one or more governmental agencies (via grants or research contracts) for which any such THIRD PARTY is a grantee, contractor, subcontractor, or collaborator under
the research program and for which DUKE is also a grantee, contractor, subcontractor or collaborator under the same contract or under a separate contract related to the same research project (provided that, notwithstanding the foregoing,
COMPANY’s approval shall not be required for provision of DUKE MATERIALS to any such governmental laboratory and/or or institution of higher learning and research that enters into one or more MTAs for the appertaining DUKE MATERIALS for the
subject research pursuant to Section 2.05(c)); and 

  

	 	(c)	 to provide to governmental laboratories and to other institutions of higher learning and research for non-commercial research purposes, but without the right to sublicense any such rights. Any such transfer of DUKE MATERIALS from Dr. Thomas Tedder’s laboratory at DUKE for activities under this
Section 2.05(c) shall be subject to one or more executed materials transfer agreements, sample forms of which are set forth in APPENDIX B attached hereto (“MTAS”). The terms of such MTAS shall not be substantially modified from the
forms attached in APPENDIX B without the prior written consent of COMPANY, such consent not to be unreasonably withheld. 

  

	 	2.06	 For avoidance of doubt, it is understood and agreed that such THIRD PARTIES associated with the foregoing
research activities described in Sections 2.05(b) and/or 2.05(c) shall be deemed to be operating under the rights retained by DUKE under Section 2.05 and shall not be deemed to be infringing DUKE PATENT RIGHTS in the performance of their
respective research activities pursuant to Sections 2.05(b) and/or 2.05(c) provided that (i) in the case of research performed by THIRD PARTIES pursuant to Section 2.05(b), the subject THIRD PARTIES

  
 8 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
shall be deemed not to be infringing DUKE PATENT RIGHTS to the extent, but only to the extent, that DUKE PATENT RIGHTS are practiced within the scope of the relevant government supported research
program, and (ii) in the case of research performed by THIRD PARTIES pursuant to Section 2.05(c), the DUKE PATENT RIGHTS are practiced in accordance with the terms of the appertaining MTA. 

 

	 	2.07	 Notwithstanding anything to the contrary in this AGREEMENT and for avoidance of doubt, it is understood and
acknowledged that nothing in this AGREEMENT shall be construed to restrict DUKE from using the KNOW-HOW as it sees fit (which shall include, but shall not be limited to, the transferring of KNOW-HOW to any THIRD PARTY, provided that in doing so it does not grant such THIRD PARTY rights to any of the DUKE PATENT RIGHTS granted to COMPANY under this AGREEMENT). 

 

	 	2.08	 The licenses granted under this AGREEMENT will not be construed to confer any rights upon COMPANY by
implication, estoppel or otherwise as to any data, technology, know-how, patents, patent applications or other property rights held by DUKE (solely or jointly) not specifically set forth herein, regardless of
whether such property rights are dominant or subordinate to any of the DUKE PATENT RIGHTS. 

  

	 	2.09	 DUKE hereby discloses to COMPANY and COMPANY acknowledges that the research leading to the INVENTIONS, DUKE
PATENT RIGHTS, and KNOW-HOW was funded in part by the U.S. Government, and the parties agree that, notwithstanding any use of descriptive terms such as “exclusive” in Section 2.01 herein and elsewhere in this AGREEMENT, the U.S.
Government has certain rights in the INVENTIONS, DUKE PATENT RIGHTS and KNOW-HOW as set forth in 37 C.F.R. §§ 401 et seq. LICENSEE agrees to comply with all obligations resulting from such government
rights, including, but not limited to, the requirement that any products sold in the United States based upon such technology be substantially manufactured in the United States. 

 

	 	2.10	 The license granted hereunder shall be subject to Public Law 96-517 and
Public Law 98-620. Any right granted in this AGREEMENT which is greater than that permitted under Public Law 96-517 and Public Law
98-620 shall be modified as may be required to conform with the provisions of those laws. 

ARTICLE 3 - LICENSE FEE, ROYALTIES AND OTHER FEES 
  

	 	3.01	 In consideration of the rights granted to COMPANY pursuant to this AGREEMENT and subject to the terms and
conditions of this AGREEMENT, COMPANY agrees to pay or otherwise compensate DUKE as follows: 

  

	 	(a)	 Equity Consideration. COMPANY shall issue to DUKE [***] ([***]) shares of COMPANY common stock, $0.001
par value per share (hereinafter, such shares referred to as the “DUKE STOCK”). COMPANY shall issue a certificate representing the DUKE STOCK directly to DUKE 

  
 9 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
in the name of “Duke University” and shall deliver such certificate evidencing the DUKE STOCK to DUKE within [***] ([***])[***] of the EFFECTIVE DATE. It is understood and agreed that,
notwithstanding anything to the contrary in this AGREEMENT, such DUKE STOCK is non-refundable. DUKE acknowledges that its interest may be diluted as a result of subsequent sales, issuances, warrant and option
grants and other potentially dilutive recapitalizations. Additionally, DUKE shall not, prior to a merger, sale, consolidation or sale of all or substantially all of the assets of COMPANY or COMPANY completing a public stock offering: (i) sell,
assign, transfer, pledge, hypothecate, mortgage, or encumber any or all of the DUKE STOCK to any THIRD PARTY other than to a DUKE AFFILIATE, or otherwise dispose of all or any of the DUKE STOCK, except with the prior written consent of COMPANY,
which consent may be denied in COMPANY’s sole discretion; or (ii) transfer any or all of the DUKE STOCK to any other person, the company, partnership, association, trust, or any other entity whatsoever other than to a DUKE AFFILIATE,
without first offering such shares of DUKE STOCK first to COMPANY on substantially similar terms and conditions, and if COMPANY does not elect to purchase all of such shares, then to any holders of COMPANY’s outstanding preferred stock, on a pro-rata basis, as set forth in that certain Amended And Restated Stock Sale and Voting Agreement, dated effective as of the EFFECTIVE DATE of this AGREEMENT (as such Amended And Restated Stock Sale and Voting
Agreement may be amended), by and between COMPANY, the Common Holders (as defined therein) and the Investors (as defined therein). As a condition to DUKE’s right to acquire DUKE STOCK, COMPANY may, in its reasonable discretion, require an
opinion of counsel for COMPANY that the proposed acquisition will be exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”), and DUKE shall have made such additional undertakings and agreements with COMPANY
as COMPANY may reasonably require, and that such other steps, if any, as counsel for COMPANY shall deem necessary to comply with any law, rule or regulation applicable to the issuance of such shares by COMPANY shall have been taken by COMPANY or
DUKE, or both. In the event that counsel for COMPANY shall issue an opinion that DUKE must make additional undertakings and agreements in order to comply with any law, rule or regulation applicable to the issuance of such shares by COMPANY, and in
DUKE’s reasonable judgment such additional undertakings and agreements are unacceptable to DUKE at that time, then DUKE may decline to acquire such shares of DUKE STOCK at that time and reserve its rights to acquire DUKE STOCK in the future.
The certificates representing the DUKE STOCK may contain such legends with respect to the foregoing restrictions as counsel for COMPANY shall deem necessary to comply with the applicable laws, rules or regulations. The same restrictions shall apply
to all of the initial holders of COMPANY’s common stock. Subject to the last sentence of this Subsection, so long as this AGREEMENT remains in effect, DUKE shall 

  
 10 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
have the right, in its discretion, to appoint one (1) representative (the “OBSERVER”) to receive notice of and to attend all meetings of the Board of Directors of COMPANY and any
committee thereof, provided that the OBSERVER may be excluded from any portion or all of any meeting of the Board or committee thereof if, in the judgment of COMPANY’s outside counsel, such attendance would eliminate the attorney-client
privilege between the COMPANY or would interfere with the exercise of the fiduciary duties of the Board. In addition, the OBSERVER shall be entitled to receive final copies of all Board and Board committee minutes and written consents. At any time
following the effectiveness of a registration statement for the sale of the COMPANY’s shares of Common Stock in a firm commitment underwritten public offering registered under the 1933 Act, the right of DUKE to appoint an OBSERVER pursuant to
this Subsection shall terminate. 

  

	 	(b)	 Royalty on NET SALES of LICENSED PRODUCTS, LICENSED PROCESSES, and LICENSED SERVICES. At the times and
in the manner set forth hereinafter, COMPANY shall pay to DUKE a non-refundable running royalty of [***] ([***]) on NET SALES of LICENSED PRODUCTS, LICENSED PROCESSES, and LICENSED SERVICES by COMPANY and/or
SUBLICENSEES (as the case may be) (hereinafter such running royalty on NET SALES OF LICENSED PRODUCTS, LICENSED PROCESSES, and LICENSED SERVICES referred to as the “DUKE RUNNING ROYALTY”). Notwithstanding the foregoing, if COMPANY (and/or
appertaining SUBLICENSEES, as the case may be) obtains, subsequent to the EFFECTIVE DATE, from any THIRD PARTY any licenses and/or sublicenses for patent rights in order to practice DUKE PATENT RIGHTS in the FIELD OF USE or in order to develop,
make, have made, use, offer for sale, sell, import, export or provide LICENSED PRODUCTS, LICENSED PROCESSES, and/or LICENSED SERVICES (as the case may be), then COMPANY (and/or appertaining SUBLICENSEES, as the case may be) shall be entitled to
credit its/their payment of additional running royalties to such THIRD PARTY(ies), if any, on LICENSED PRODUCTS, LICENSED PROCESSES, and/or LICENSED SERVICES (as the case may be) against the DUKE RUNNING ROYALTY for the subject LICENSED PRODUCTS,
LICENSED PROCESSES, and/or LICENSED SERVICES (as the case may be) in the appertaining country(ies) during the appertaining time period, provided that, notwithstanding the foregoing, in no event shall the amount payable to DUKE as DUKE RUNNING
ROYALTY on NET SALES of LICENSED PRODUCTS, LICENSED PROCESSES, and LICENSED SERVICES by COMPANY and/or SUBLICENSEES (as the case may be) be reduced to less than [***] ([***]) for the subject LICENSED PRODUCTS, LICENSED PROCESSES, and/or LICENSED
SERVICES (as the case may be) in the appertaining country(ies) during the appertaining time period. Notwithstanding the foregoing and for the sake of clarification, it is understood and agreed that any license/sublicense agreement involving

  
 11 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
COMPANY (and/or its SUBLICENSEES, as the case may be) and the Dana-Farber Cancer Institute covering any technology and/or inventions for which Dr. Thomas Tedder was an inventor prior to the
EFFECTIVE DATE including, but not limited to, U.S. Patent No. 5,484,892 (hereinafter such license/sublicense agreement(s) to be referred to as “COMPANY(SUBLICENSEE)/DFCI TEDDER TECHNOLOGY LICENSE AGREEMENT(S)”) shall be considered to
be made prior to the EFFECTIVE DATE of this AGREEMENT regardless of the effective date of any of such COMPANY(SUBLICENSEE)/DFCI TEDDER TECHNOLOGY LICENSE AGREEMENT(S) and/or execution date of the same by COMPANY (and/or SUBLICENSEE, as the
case may be) and/or Dana-Farber Cancer Institute, and, thus, no reduction in the DUKE RUNNING ROYALTY shall apply with respect to COMPANY (SUBLICENSEE)/DFCI TEDDER TECHNOLOGY LICENSE AGREEMENT as a result of the application of the foregoing
stacking provision. 

  

	 	(c)	 Milestone Payments. 

(i) With respect to any LICENSED PRODUCT or LICENSED SERVICE that practices or whose intended use practices an INVENTION claimed in the CD22
APPLICATIONS (as defined in APPENDIX A) and/or in patents in the DUKE PATENT RIGHTS arising therefrom and for which regulatory approval is being sought for such intended use, COMPANY shall make the following milestone payments to DUKE within [***]
([***]) [***] of it and/or its SUBLICENSEE(S) (as the case may be) first achieving the following significant regulatory and commercialization milestones: 
  

	 	(A)	 U.S.$ [***] 

  

	 	(B)	 U.S.$ [***] 

  

	 	(C)	 U.S.$ [***] 

  

	 	(D)	 U.S.$ [***] 

(ii) With respect to any LICENSED PRODUCT or LICENSED SERVICE that practices or whose intended use practices an INVENTION claimed in the CD20
APPLICATIONS (as defined in APPENDIX A) and/or in patents in the DUKE PATENTS and for which regulatory approval is being sought for such intended use, COMPANY shall make the following milestone payments to DUKE within [***] ([***]) [***] of it
and/or its SUBLICENSEE(S) (as the case may be) first achieving the following significant regulatory and commercialization milestones: 
  

	 	(A)	 U.S.$ [***] 

  
 12 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(B)	 U.S.$ [***] 

  

	 	(C)	 U.S.$ [***] 

  

	 	(D)	 U.S.$ [***] 

(iii) With respect to any LICENSED PRODUCT or LICENSED SERVICE that practices or whose intended use practices an INVENTION claimed in the CD19
APPLICATIONS (as defined in APPENDIX A) and/or in patents in the DUKE PATENTS and for which regulatory approval is being sought for such intended use, COMPANY shall make the following milestone payments to DUKE within [***] ([***]) [***] of it
and/or its SUBLICENSEE(S) (as the case may be) first achieving the following significant regulatory and commercialization milestones: 
  

	 	(A)	 U.S.$ [***] 

  

	 	(B)	 U.S.$ [***] 

  

	 	(C)	 U.S.$ [***] 

  

	 	(D)	 U.S.$ [***] 

(iv) With respect to any LICENSED PRODUCT or LICENSED SERVICE that practices or whose intended use practices an INVENTION claimed in the MS4a
APPLICATIONS (as defined in APPENDIX A) and/or in patents in the DUKE PATENTS and for which regulatory approval is being sought for such intended use, COMPANY shall make the following milestone payments to DUKE within [***] ([***]) days of it and/or
its SUBLICENSEE(S) (as the case may be) first achieving the following significant regulatory and commercialization milestones: 
  

	 	(A)	 U.S.$ [***] 

  

	 	(B)	 U.S.$ [***] 

  

	 	(C)	 U.S.$ [***] 

  

	 	(D)	 U.S.$ [***] 

For avoidance of doubt, it is understood and agreed that the milestone payments set forth in Sections 3.01 (c) (i)-(iv) above (aa) shall be
credited only to the stated milestone and no other, (bb) shall not be creditable against DUKE RUNNING ROYALTIES or any other payments, fees, reimbursements, or the like due to DUKE under this AGREEMENT, (cc) shall be non-refundable, and (dd) shall not be subject to any stacking or other provision which may diminish the amounts set forth above, other than the provisions of Section 4.03(c)(iii)(C) (respecting
reductions resulting from the conversion of a LICENSE from exclusive to nonexclusive). 

  
 13 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	3.02	 Notwithstanding reports, correspondence or other communications from COMPANY, it is understood that DUKE shall,
in accordance with its policies and procedures, apply any amounts received from COMPANY under the terms of this AGREEMENT as follows: 

  

	 	(a)	 first to reimbursable expenses, including but not limited to applicable DUKE PATENT RIGHTS EXPENSES as set
forth in Article 6 herein; and 

  

	 	(b)	 thereafter to such DUKE RUNNING ROYALTIES, milestone payments, and other payments as may be due in accordance
with all the terms of this AGREEMENT. 

 Application of amounts received under (a) above shall in no respect alter the
aggregate amount due to DUKE. 
  

	 	3.03	 Notwithstanding anything to the contrary in this AGREEMENT, except as expressly set forth in Section 1.16,
all payments due hereunder shall be paid in full, without deduction of taxes or other fees which may be imposed by any government and which shall be paid by COMPANY (and/or appertaining SUBLICENSEES, as the case may be). 

 

	 	3.04	 All payments due from COMPANY pursuant to this AGREEMENT shall be due and payable in accordance with the terms
and conditions of this AGREEMENT, and if a payment due pursuant to this AGREEMENT is not paid within [***] ([***]) [***] of the payment due date, any such past due amount shall bear interest at the total rate of the [***], as the case may be) plus
[***] ([***]) as of the due date of such payment unless such total rate of interest exceeds the [***] under appertaining North Carolina law, in which case the [***] of interest under appertaining North Carolina law shall apply. The payment of such
interest shall not foreclose DUKE from exercising any other rights it may have as a consequence of the lateness of any payment. 

  

	 	3.05	 No multiple royalties on NET SALES shall be payable to DUKE on a single LICENSED PRODUCT, LICENSED PROCESS
and/or LICENSED SERVICE based on the fact that such LICENSED PRODUCT, LICENSED PROCESS and/or LICENSED SERVICE (or the manufacture, having manufactured, use, importation, export, or sale thereof) practices more than one of the INVENTIONS, more than
one claim in any of the DUKE PATENT RIGHTS, and/or more than one of the DUKE PATENT RIGHTS. 

  

	 	3.06	 All payments due to DUKE under this, AGREEMENT shall be paid in United States Dollars in Durham, North
Carolina, or at such place as DUKE may reasonably designate consistent with the laws and regulations controlling in any foreign country. If any currency conversion shall be required in connection with such payments due hereunder, such conversion
shall be made by using the exchange 

  
 14 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
rate prevailing at [***] ([***], as the case may be) on the last business day of the reporting period to which such payments relate. If payments are made by wire, electronic or other transfer
form for which a fee is charged (“PAYMENT TRANSFER FEES”), COMPANY shall be responsible for the full amount of such PAYMENT TRANSFER FEES and shall use reasonable efforts to pay such fees prior to or at the time of such transfer so that
the PAYMENT TRANSFER FEES are not passed on to DUKE. In the event that any such PAYMENT TRANSFER FEES are paid by DUKE, COMPANY shall pay promptly reimburse DUKE for DUKE’s payment of such PAYMENT TRANSFER FEES within [***] ([***]) [***] of
COMPANY’s receipt of invoice of the same from DUKE. 

  

	 	3.07	 Payments due to DUKE pursuant to Sections 3.01(b) or 3.01(c) and/or otherwise relating to DUKE PATENT RIGHTS
shall cite the appertaining DUKE File numbers. All payments due to DUKE under this AGREEMENT shall be made payable to “Duke University.” Payments may be made by wire or electronic transfer, provided that an accompanying notice is delivered
with reference to the pertinent DUKE file numbers and PAYMENT TRANSFER FEES associated with such wire or electronic transfer are paid in full by COMPANY (and/or appertaining SUBLICENSEES, as the case may be) at the time of such transfer or within
[***] ([***]) [***] of receipt of invoice from DUKE for the same as set forth in Section 3.06. All payments due to DUKE, as well as reports due to DUKE in accordance with Sections 5.02 and 5.03, shall be sent to DUKE at the following address:

 For delivery via the U.S. Postal Service: 

Duke University Office of Science and Technology 

Attention: Financial Administrator 

Box 90083 Duke University 

Durham, NC 27708 USA 
 For
delivery via nationally/internationally recognized courier: 
 Duke University Office of Science and Technology 

Attention: Financial Administrator 

2020 West Main Street, Suite 10 

Durham, NC 27705 USA 
 For
payment via wire transfer: 
  

					
	                  	  	[***]:                            	  	[***]
		  		  	[***]
		  	[***]	  	[***]
		  	[***]:	  	[***]
		  	[***]:	  	[***]
		  	[***]:	  	[***]
		  	[***]:	  	[***]

  
 15 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ARTICLE 4 - DUE DILIGENCE REQUIREMENTS 

 

	 	4.01	 COMPANY shall deliver to DUKE a draft of COMPANY’s business plan within [***] ([***]) [***] of the
EFFECTIVE DATE and a final version of COMPANY’s business plan within [***] ([***]) [***] of the EFFECTIVE DATE (hereinafter, the “FINAL COMPANY BUSINESS PLAN”). 

 

	 	4.02	 COMPANY shall exert commercially reasonable efforts to bring LICENSED PRODUCTS and/or LICENSED SERVICES to
market based on the INVENTIONS claimed in the DUKE PATENT RIGHTS and to pursue any required government approvals, and shall continue commercially reasonable active, diligent sales and marketing efforts throughout the life of this AGREEMENT.
COMPANY’s diligence will be demonstrated by mutually agreed upon performance obligations to be negotiated in good faith between COMPANY and DUKE, and shall include, but shall not be limited to, such measures as dates by which COMPANY will have
acquired specific amounts of funding, dates and/or milestones by which reasonable levels of commercialization will be achieved (hereinafter, such performance obligations and associated time frames for achievement by COMPANY hereinafter referred to
as “COMPANY PERFORMANCE MILESTONE SCHEDULE”), such COMPANY PERFORMANCE MILESTONE SCHEDULE to be documented in writing and attached hereto as APPENDIX C. Negotiation of COMPANY PERFORMANCE MILESTONE SCHEDULE shall be in good faith based
upon the FINAL COMPANY BUSINESS PLAN and reasonable commercial expectations and shall commence by COMPANY providing DUKE with a draft of proposed COMPANY PERFORMANCE MILESTONE SCHEDULE within [***] ([***]) [***] of DUKE’s receipt of the FINAL
COMPANY BUSINESS PLAN. COMPANY and DUKE will use reasonable best efforts to conclude the negotiation of COMPANY PERFORMANCE MILESTONE SCHEDULE within [***] ([***]) [***] of DUKE’s receipt of the first draft of the proposed COMPANY PERFORMANCE
MILESTONE SCHEDULE. 

  

	 	4.03	 COMPANY shall notify DUKE in writing if COMPANY reasonably believes that it will miss the date of any milestone
set forth in COMPANY PERFORMANCE MILESTONE SCHEDULE in APPENDIX C by more than [***] ([***]) [***]. If any milestone set forth in COMPANY PERFORMANCE MILESTONE SCHEDULE is not reached within [***] ([***]) [***] after the stated time period for such
milestone set out in APPENDIX C, or within those amended periods of time approved in writing by DUKE (“AMENDED COMPANY PERFORMANCE MILESTONE TARGET PERIOD”), then: 

 

	 	(a)	 COMPANY shall notify DUKE in writing within [***] ([***]) [***] following the expiration of the [***] ([***])
[***] (or AMENDED COMPANY PERFORMANCE MILESTONE TARGET PERIOD, as the case may be) of COMPANY’s failure to meet such milestone, which notification shall include a description of COMPANY’s progress to date toward achieving such milestone,
the reason(s) (if known) for COMPANY’s inability to meet such milestone to date, and a good faith estimate of additional time needed by COMPANY to achieve such milestone; 

  
 16 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(b)	 COMPANY and DUKE shall engage in good faith discussions during the [***] ([***]) [***] following DUKE’s
receipt of the written notice (provided pursuant to Subsection 4.03(a) above) (“COMPANY PERFORMANCE MILESTONE RE-NEGOTIATION PERIOD”) to determine whether the parties can agree upon a mutually
acceptable extension of time for COMPANY to achieve such milestone; 

  

	 	(c)	 if COMPANY and DUKE are unable to agree in writing upon a mutually acceptable extension of time for COMPANY to
meet the appertaining milestone by the end of the appertaining COMPANY PERFORMANCE MILESTONE RE-NEGOTIATION PERIOD, then DUKE may, at its sole discretion, convert the exclusive LICENSE respecting the DUKE
PATENT RIGHTS, LICENSED PRODUCT(S), LICENSED PROCESS(ES) and/or LICENSED SERVICE(S) to which such milestone pertained (hereinafter such DUKE PATENT RIGHTS, LICENSED PRODUCT(S), LICENSED PROCESS(ES) and/or LICENSED SERVICE(S) to which such milestone
pertained referred to collectively as “CONVERTIBLE RIGHTS”) to a non-exclusive LICENSE; provided, however, that: 

(i) DUKE shall exercise such conversion right, if at all, within [***] ([***]) [***] following the expiration of the appertaining COMPANY
PERFORMANCE MILESTONE RE-NEGOTIATION PERIOD by written notice to COMPANY; 
 (ii) if DUKE exercises
such conversion right and converts the applicable exclusive LICENSE to a nonexclusive license, such conversion shall apply only to the CONVERTIBLE RIGHTS and only to extent that such CONVERTIBLE RIGHTS are not practiced, embodied, or utilized
in a LICENSED PRODUCT, LICENSED PROCESS, and/or LICENSED SERVICE for which COMPANY has, as of the time of potential conversion of such CONVERTIBLE RIGHTS, achieved all applicable milestones set forth in the COMPANY PERFORMANCE MILESTONE SCHEDULE
within [***] ([***]) [***] of the dates set forth therein or within the appertaining AMENDED COMPANY PERFORMANCE MILESTONE TARGET PERIOD(S), or as set forth in Section 4.03(d); 

(iii) upon any such conversion by DUKE of any exclusive LICENSE to a nonexclusive LICENSE pursuant to this Subsection 4.03, then from and
after the effective date of such conversion: 
  

	 	(A)	 The percentage royalty rate used to compute DUKE RUNNING ROYALTIES (pursuant to Subsection 3.01(b) above) shall
be reduced from [***] ([***]) [***] ([***]) of NET SALES of the affected LICENSED PRODUCT, LICENSED PROCESS or LICENSED SERVICE in the affected country(ies) (before any reduction for stacking of THIRD-PARTY license royalties pursuant to such
Subsection). 

  
 17 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(B)	 COMPANY and/or its appertaining SUBLICENSEES (as the case may be) shall be permitted to credit any running
royalties paid to THIRD PARTIES on the affected LICENSED PRODUCTS, LICENSED PROCESSES and/or LICENSED SERVICES (as the case may be) against such DUKE RUNNING ROYALTIES (as reduced pursuant to Subsection 4.03(c)(iii)(A) above)); provided,
however, that in no event shall the amount payable to DUKE as DUKE RUNNING ROYALTY on NET SALES of the affected LICENSED PRODUCT, LICENSED PROCESS, or LICENSED SERVICE (as the case may be) by COMPANY and/or SUBLICENSEES (as the case may be)
be reduced to less than [***] ([***]) for the subject LICENSED PRODUCT, LICENSED PROCESS, and/or LICENSED SERVICE (as the case may be) in the appertaining country(ies) during the appertaining time period. 

 

	 	(C)	 Any future milestone payments under Subsection 3.01(c) applicable to such LICENSED PRODUCT, LICENSED PROCESS
and/or LICENSED SERVICE (as the case may be) shall be reduced by [***] ([***]) of the amounts set forth in such Subsection. 

  

	 	(D)	 The reductions set forth in Subsections 4.03(c)(iii)(A) through (C) shall apply only to those LICENSED
PRODUCTS, LICENSED PROCESSES, and/or LICENSED SERVICES that are solely covered by the nonexclusive LICENSE resulting from such conversion. For purposes of illustration and clarification of this Subsection 4.03(c)(iii)(D), if a LICENSED PRODUCT
covered by DUKE PATENT RIGHTS to which COMPANY holds an exclusive LICENSE and DUKE PATENT RIGHTS to which COMPANY holds a nonexclusive LICENSE (following a conversion of such LICENSE by DUKE pursuant to this Subsection 4.03), then the
percentage royalty rate used to compute the DUKE RUNNING ROYALTY on NET SALES of such LICENSED PRODUCT and any appertaining milestone payments due DUKE for such LICENSED PRODUCT shall not be reduced pursuant to Subsections 4.03(c)(iii)(A) through
(C) above. 

  

	 	(E)	 Within [***] ([***]) [***] following COMPANY’s receiving written notification from DUKE of any such
conversion, COMPANY shall assign to DUKE all exclusive SUBLICENSES to the extent such exclusive SUBLICENSES pertain to LICENSED PRODUCTS, LICENSED PROCESSES, and/or LICENSED SERVICES to which COMPANY’s LICENSE from DUKE has been converted from
exclusive to nonexclusive. For avoidance of 

  
 18 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
doubt, if the subject matter of any such exclusive SUBLICENSE is limited solely to LICENSED PRODUCTS, LICENSED PROCESSES, and/or LICENSED SERVICES to which COMPANY’s LICENSE from DUKE has
been converted from exclusive to nonexclusive, then COMPANY shall assign such exclusive SUBLICENSE to DUKE in its entirety; however, if the subject matter of any such exclusive SUBLICENSE includes LICENSED PRODUCTS, LICENSED PROCESSES, and/or
LICENSED SERVICES to which COMPANY’s LICENSE from DUKE has been converted from exclusive to nonexclusive and LICENSED PRODUCTS, LICENSED PROCESSES, and/or LICENSED SERVICES to which no such conversion is applicable, then COMPANY shall
make a partial assignment of such exclusive SUBLICENSE to DUKE to effect an assignment only of those rights to which such conversion pertained. Following any such assignment or partial assignment, as the case may be, COMPANY’s rights under this
AGREEMENT to the appertaining rights sublicensed exclusively to the subject SUBLICENSEES (and converted to nonexclusive as to COMPANY pursuant to this Section 4.03) shall terminate as of the effective date of the appertaining assignment(s) or
partial assignment(s), as the case may be, to DUKE. 

  

	 	(F)	 For any rights that COMPANY retains following any conversion by DUKE pursuant to this Section 4.03,
COMPANY will still be responsible to DUKE for any DUKE RUNNING ROYALTY payments and payments with respect to non-royalty income, subject to the applicable reductions set forth above. 

 

	 	(G)	 COMPANY shall be responsible for payment of a pro rata share (computed as set forth below) of all DUKE PATENT
RIGHTS EXPENSES for the DUKE PATENT RIGHTS to which the conversion pertained. COMPANY’s pro rata share of such DUKE PATENT RIGHTS EXPENSES shall be equal to 1/n of all DUKE PATENT RIGHTS EXPENSES incurred by DUKE after the effective date
of such conversion in connection with the filing, prosecution and maintenance of the DUKE PATENT RIGHTS to which such conversion pertained, where “n” is the total number of organizations holding, at the time any such DUKE PATENT
RIGHTS EXPENSES are incurred, an active license from DUKE under the DUKE PATENT RIGHTS giving rise to the DUKE PATENT RIGHTS EXPENSES. For purposes of computing the value of “n,” the number of SUBLICENSEES shall not be included.

 (iv) DUKE’s failure to exercise such right of conversion with respect to any CONVERTIBLE RIGHTS shall not
constitute a waiver of such conversion right with respect to any subsequent failure by COMPANY to achieve any subsequent milestone. 

  
 19 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (v) Notwithstanding any provision contained in this AGREEMENT to the contrary,
COMPANY’s failure to meet any performance milestone set forth in APPENDIX C shall not be deemed an event of default by COMPANY giving rise to any right of termination of this AGREEMENT by DUKE pursuant to Article 10. Rather, DUKE’s rights
and remedies for a failure by COMPANY to achieve any milestone set forth in APPENDIX C shall be limited to the conversion rights set forth in this Section 4.03. 
  

	 	(d)	 Notwithstanding the foregoing provisions of this Section 4.03, in the event COMPANY achieves such
milestone prior to DUKE’s exercise of any applicable right of conversion as evidenced by DUKE’s receipt of written documentation from COMPANY of such achievement prior to the date of DUKE’s exercise of the applicable right of
conversion, then such milestone shall be deemed to have been met for purposes of this AGREEMENT and DUKE’s right to convert the appertaining LICENSE(S) to nonexclusive shall terminate with respect to such milestone. 

 

	 	4.04	 During the term of this AGREEMENT, COMPANY will submit annual progress reports to DUKE as set forth in
Section 5.02. DUKE shall have the right to request one (1) meeting per year to discuss such information with representatives of COMPANY at mutually acceptable times and places. It is agreed that should any of DUKE’s personnel be
required by COMPANY to consult with COMPANY outside of Durham, North Carolina, COMPANY will reimburse reasonable travel and living expenses incident thereto. 

ARTICLE 5 - REPORTS AND RECORDS 
  

	 	5.01	 COMPANY shall keep full, true and accurate books of accounts and other records containing all particulars which
may be necessary to properly ascertain and verify the amounts payable to DUKE hereunder and shall require SUBLICENSEES, as the case may be, to do the same. Said books of account shall be kept at COMPANY’s (and/or SUBLICENSEES’) principal
place of business or the principal place of business of the appropriate division of COMPANY (and/or SUBLICENSEE) to which this AGREEMENT relates. Said books and the supporting data shall be open at mutually agreed upon times during regular business
hours for [***] ([***]) [***] following the end of the calendar year to which they pertain, to the inspection of DUKE or a mutually acceptable certified public accountant for the purpose of verifying COMPANY’s (and/or SUBLICENSEE’s)
royalty statement or compliance in other respects with this AGREEMENT. Should such inspection lead to the discovery of a greater than [***] ([***]) discrepancy in reporting, COMPANY agrees to reimburse DUKE for the out-of-pocket cost of such inspection in addition to any amounts due to DUKE, such amounts to be subject to the provisions of Section 3.04. 

 

	 	5.02	 COMPANY shall report the status of development of each LICENSED PRODUCT annually to DUKE by [***] of each year.
Such report shall include descriptions of COMPANY’s (and/or SUBLICENSEES’, as the case may be) plans and commercially reasonable estimated timeframes for testing, development, governmental approvals and marketing/sale of each LICENSED
PRODUCT. 

  
 20 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	5.03	 After the first commercial sale of a LICENSED PRODUCT, and in addition to the reports required under
Section 5.02, COMPANY shall render to DUKE prior to [***] and [***] of each year a written account of the NET SALES of LICENSED PRODUCTS and/or LICENSED SERVICES made by COMPANY and/or SUBLICENSEES (as the case may be) by during the prior six-month period ending [***] and [***], respectively, and shall simultaneously pay to DUKE the DUKE RUNNING ROYALTIES due on such NET SALES of LICENSED PRODUCTS and/or LICENSED SERVICES in United States dollars.
Reports tendered shall include the calculation of DUKE RUNNING ROYALTIES by product by country in substantially the format provided in APPENDIX D hereto. 

ARTICLE 6 - PATENTS 
  

	 	6.01	 Patent Prosecution 

 

	 	(a)	 Except as expressly set forth in Section 6.01(b), DUKE shall, at its sole discretion, apply for,
prosecute, and maintain the DUKE PATENT RIGHTS during the term of this AGREEMENT. DUKE will use reasonable commercial efforts to file, prosecute and maintain the DUKE PATENT RIGHTS. DUKE will keep COMPANY advised as to all developments with respect
to, and will promptly deliver to COMPANY (or cause DUKE’s patent counsel promptly to deliver to COMPANY) all official documents and correspondence relating to the prosecution of, the DUKE PATENT APPLICATIONS, and/or applicable or related
continuation, continuation-in-part and reissue application(s) within the DUKE PATENT RIGHTS and respecting the maintenance and validity of all DUKE PATENTS issued or
issuing with respect thereto. COMPANY will have (i) the right to review DUKE PATENT APPLICATIONS and to make recommendations regarding the prosecution of such DUKE PATENT APPLICATIONS, (ii) the right to receive such DUKE PATENT
APPLICATIONS and related official documentations at such time as to allow a reasonable period for review thereof prior to any applicable deadline for filing or responding, and (iii) the right to request amendments of any such DUKE PATENT
APPLICATION to include claims or arguments as may be appropriate for obtaining a patent claiming commercially relevant inventions. Upon request by DUKE and/or its agents, COMPANY shall promptly inform DUKE in writing which non-U.S. countries, if any, in which COMPANY desires patent protection and DUKE PATENT RIGHTS shall reflect such designations provided that COMPANY bears the associated costs as set forth in Section 6.02(a).
DUKE may elect to seek patent protection in countries not so designated by COMPANY, in which case DUKE shall notify COMPANY in writing of such election, and from the date of such filing of such DUKE PATENT APPLICATIONS by DUKE in such undesignated
countries, such DUKE PATENT APPLICATIONS and 

  
 21 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
resulting patents shall not be considered DUKE PATENT RIGHTS (and/or DUKE PATENT APPLICATIONS) in such countries and COMPANY shall be deemed to have forfeited all rights under this AGREEMENT to
such DUKE PATENT APPLICATIONS and resulting patents in such countries. (APPENDIX A shall be deemed to be so amended.) It is understood and agreed that all final decisions with respect to prosecution and maintenance of DUKE PATENT RIGHTS are reserved
to DUKE. 

  

	 	(b)	 COMPANY shall have the right to assume primary responsibility for all activities associated with the
prosecution S of DUKE PATENT RIGHTS during the term of this AGREEMENT, provided that it first provides DUKE with written notice of its desire to assume such responsibilities and obtains DUKE’s written approval of the legal counsel that COMPANY
shall retain for such purposes, such approval not to be unreasonably withheld or delayed. It is understood and agreed that in the event COMPANY assumes such responsibilities pursuant to this Section 6.01(b), COMPANY shall keep DUKE advised as
to the status of the DUKE PATENT RIGHTS and COMPANY’s designated patent attorneys will provide DUKE, in a timely manner, with copies of all official documents and correspondence relating to the prosecution, maintenance, and validity of the
appertaining DUKE PATENT RIGHTS. COMPANY shall consult with DUKE in such prosecution and maintenance, shall diligently seek advice of DUKE on all matters pertaining to the DUKE PATENT RIGHTS, shall diligently seek appropriate claims under the DUKE
PATENT RIGHTS, and shall not abandon prosecution of any DUKE PATENT RIGHTS without first notifying DUKE in a timely manner of COMPANY’s intention and reason therefor, and providing DUKE with reasonable opportunity to assume responsibility for
prosecution and maintenance of the appertaining DUKE PATENT RIGHTS (which thereafter shall be subject to the provisions of Section 6.02(b) as regards status as DUKE PATENT RIGHTS and LICENSED PRODUCTS, LICENSED PROCESSES, and LICENSED SERVICES
and COMPANY’s rights therein). Notwithstanding the foregoing or anything to the contrary in this AGREEMENT, it is understood and agreed all final decisions with respect to the prosecution and maintenance of the DUKE PATENT RIGHTS by COMPANY
pursuant to this Section 6.01(b) shall be made by DUKE. COMPANY’s obligations under this Section 6.01(b) shall include, without limitation, an obligation to inform DUKE in a timely manner (no less than [***] ([***]) [***] prior to the
appertaining filing deadlines) that COMPANY will not pursue patents in any non-US country so that DUKE may pursue such patents if it so desires in which case, from the date of such filing of such PATENT
APPLICATIONS by DUKE, such PATENT APPLICATIONS and resulting DUKE PATENTS shall not be considered DUKE PATENT RIGHTS in such non-U.S. country and COMPANY shall be deemed to have forfeited all rights under this
AGREEMENT to such PATENT APPLICATIONS and resulting DUKE PATENTS in such non-U.S. country (APPENDIX A). For avoidance of doubt, it is understood that COMPANY shall assume direct and full responsibility for
payment of DUKE PATENT RIGHTS EXPENSES it incurs as a result of its assumption of responsibility for prosecution of DUKE PATENT RIGHTS under this Section 6.01(b). 

  
 22 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	6.02	 Patent Costs. 

 

	 	(a)	 During the term of this AGREEMENT, payment of all DUKE PATENT RIGHTS EXPENSES relating to the filing,
prosecution, and maintenance of the DUKE PATENT RIGHTS shall be the responsibility of COMPANY, whether such DUKE PATENT RIGHTS EXPENSES were incurred before or after the EFFECTIVE DATE of this AGREEMENT. Notwithstanding anything to the contrary in
this AGREEMENT, except in cases in which COMPANY declines interest in non-U.S. patent pursuit, COMPANY shall be responsible for all DUKE PATENT RIGHTS EXPENSES associated with the preparation and filing of the
PCT application(s) contained within the DUKE PATENT RIGHTS as well as all DUKE PATENT RIGHTS EXPENSES associated with pursuit and maintenance of the DUKE PATENT RIGHTS. COMPANY will pay all such DUKE PATENT RIGHTS EXPENSES within [***] ([***]) [***]
of receipt of an invoice for the same, and failure to pay each such invoice within such [***] ([***]) [***] period shall be a default hereunder for which DUKE may terminate this AGREEMENT in accordance with Section 10.04. In addition to the
foregoing, within [***] ([***]) [***] of the EFFECTIVE DATE of this AGREEMENT, COMPANY shall pay to DUKE the amount of [***] (U.S.$ [***]) as reimbursement for DUKE PATENT RIGHTS EXPENSES that were incurred by DUKE and for which the invoices had
been received and processed by DUKE before the EFFECTIVE DATE. If at any time COMPANY fails to reimburse DUKE for any DUKE PATENT RIGHTS EXPENSES within the [***] ([***]) [***] period following receipt of a subject invoice, then henceforth during
the term of this AGREEMENT, DUKE may, at its sole discretion, require COMPANY to make payment for estimated associated DUKE PATENT RIGHTS EXPENSES (which estimates shall reasonably be made in good faith by the patent counsel prosecuting the DUKE
PATENT RIGHTS) prior to incurring such DUKE PATENT RIGHTS EXPENSES, including, but without limitation, DUKE PATENT RIGHTS EXPENSES associated with national phase filings of DUKE PATENT APPLICATIONS, preparation and filing of responses to
patent office actions on DUKE PATENT APPLICATIONS, such requirement by DUKE not to preclude DUKE from exercising any other recourse it may have under this AGREEMENT as regards lack of prompt reimbursement of DUKE PATENT RIGHTS EXPENSES by COMPANY.

  

	 	(b)	 If COMPANY decides to discontinue the financial support of the prosecution or maintenance of a subject DUKE
PATENT APPLICATION or patent falling within the scope of DUKE PATENT RIGHTS, COMPANY will give DUKE timely written notice at least [***] ([***]) [***] in advance of the effective date of COMPANY’s decision and DUKE

  
 23 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
will be free to continue prosecution or maintenance of any such DUKE PATENT APPLICATION(S) or DUKE PATENT(S) as the case may be, and to maintain any protection issuing thereon in the U.S. and in
any foreign country at DUKE’s sole expense. In such instances, from the effective date specified in such written notice from COMPANY, such DUKE PATENT(S) and/or DUKE PATENT APPLICATION(S) shall no longer be considered to fall within the
definition of DUKE PATENT RIGHTS (APPENDIX A shall be deemed to be so amended) and COMPANY shall forfeit all rights under this AGREEMENT to the subject issued DUKE PATENT(s) and/or subject DUKE PATENT APPLICATIONS and DUKE PATENT(s) arising from
such DUKE PATENT APPLICATIONS. Accordingly, DUKE shall be free to license such DUKE PATENT(s) and DUKE PATENT APPLICATIONS to THIRD PARTIES or otherwise dispose of such DUKE PATENT(s) and DUKE PATENT APPLICATION(S) as it deems appropriate.

  

	 	6.03	 COMPANY agrees to mark the LICENSED PRODUCTS, and/or their containers, labels, and/or other packaging (as the
case may be), in such a manner as to conform to the patent laws and regulations of the country of manufacture or sale, as appropriate. 

ARTICLE 7 - INFRINGEMENT OF THIRD-PARTY RIGHTS 
  

	 	7.01	 In the event that DUKE or COMPANY is charged with infringement of a patent by a THIRD PARTY or is made a party
in a civil action as a result of the activity of COMPANY and/or a SUBLICENSEE (and not from the activity of DUKE or its AFFILIATES other than the granting of the LICENSES to COMPANY) as a result (directly or indirectly) of the LICENSES granted
hereunder to COMPANY, COMPANY: 

  

	 	(a)	 must defend and/or settle any such claim of infringement or civil action; 

 

	 	(b)	 shall have the right to control the defense of any such claim or action; 

 

	 	(c)	 must assume all costs, expenses, damages, and other obligations for payments incurred as a consequence of such
charges of infringement and/or civil action; 

  

	 	(d)	 must indemnify and hold DUKE harmless from any and all damages, losses, liability, and costs resulting from a
charge of infringement or civil action which shall be brought against DUKE and attributable to technology added to, incorporated into or sold with a LICENSED PRODUCT and/or LICENSED SERVICE by COMPANY, and/or SUBLICENSEE (as the case may be) or to
manufacturing processes utilized by COMPANY or SUBLICENSEE (as the case may be); and 

  

	 	(e)	 may, if such claim of infringement or civil action shall be based on patent claims contained in any pending or
issued patent included in the DUKE PATENT RIGHTS, terminate this AGREEMENT effective immediately upon DUKE’s receipt of written notice of termination. 

  
 24 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 For avoidance of doubt, COMPANY shall have no obligation to indemnify, defend, or hold
harmless DUKE from or against any claims, damages, or civil actions to the extent, and only to the extent, that such claims, damages, and/or civil actions are caused by the negligence or willful misconduct of DUKE, DUKE employees, DUKE faculty
members, students, and/or agents acting solely within the performance of their respective responsibilities at DUKE. 
  

	 	7.02	 DUKE will give COMPANY reasonable assistance, at COMPANY’s expense, in the defense of any such
infringement charge or lawsuit, as may be reasonably required. COMPANY shall reimburse DUKE for such expenses within [***] ([***]) [***] of receiving an invoice for the same. 

ARTICLE 8 -INFRINGEMENT OF DUKE PATENT RIGHTS BY THIRD PARTIES 
  

	 	8.01	 Each party to this AGREEMENT is obligated to inform the other promptly in writing of any alleged infringement
of which it becomes aware and of any available evidence of infringement by a THIRD PARTY of any patents within the DUKE PATENT RIGHTS. 

  

	 	8.02	 If during the term of this AGREEMENT, COMPANY becomes aware of any alleged infringement by a THIRD PARTY,
COMPANY shall have the right, but not the obligation, to either: 

  

	 	(a)	 settle the infringement suit by sublicensing the alleged infringer or by other means; or 

 

	 	(b)	 prosecute at its own expense any infringement of the DUKE PATENT RIGHTS, when, in its judgment, such action may
be reasonably necessary and justified. In the event COMPANY prosecutes such infringement of DUKE PATENT RIGHTS, COMPANY may, for such purposes and subject to the express, prior written approval of DUKE (such approval not to be unreasonably withheld
or delayed), use the name of DUKE as party plaintiff; provided, however, that all costs associated therewith shall be borne by COMPANY. 

DUKE, at its sole discretion, may join any legal proceeding brought by COMPANY under this Article, using DUKE’s own counsel and at
DUKE’s own expense. If DUKE elects to join as a party plaintiff pursuant to this Article, DUKE may jointly participate in the action with COMPANY, but COMPANY’s counsel will be lead counsel. 

 

	 	8.03	 In the event COMPANY initiates legal proceedings against an infringer and DUKE does not join the proceeding,
COMPANY may deduct up to [***] ([***]) of COMPANY’s documented out-of-pocket costs and expenses of the proceeding (including reasonable attorneys’ fees) from
the DUKE RUNNING ROYALTY in respect of NET SALES of the subject LICENSED PRODUCTS or LICENSED SERVICES in the appertaining countries covered by the patent(s)-in-suit.

  
 25 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	8.04	 In any such legal proceeding brought by COMPANY, DUKE or jointly by COMPANY and DUKE, any recovery or proceeds
of such proceeding, whether characterized as damages, costs, attorneys’ fee awards or otherwise, will be distributed as follows: (a) each party will first be reimbursed pro rata for its reasonable attorneys’ fees and out-of-pocket expenses actually incurred in connection with the proceeding, including but not limited to, DUKE’s recovery of a sum equivalent to the total amount of DUKE
RUNNING ROYALTIES, if any, deducted by COMPANY under Section 8.03 above; (b) COMPANY will second recover an amount equal to its lost profits or a reasonable royalty (whichever measure of damages has been applied in the legal proceeding or
settlement thereof); (c) DUKE will then receive the amount for DUKE RUNNING ROYALTIES that COMPANY would have owed to DUKE if COMPANY, or if COMPANY has granted a sublicense respecting the patent(s)-in-suit, such sublicensee, had made the infringer’s sales directly, to the extent such award compensates COMPANY for such sales or lost profit on such sales or such reasonable royalties on such
sales, provided that the amount of such DUKE RUNNING ROYALTIES shall not exceed the amount of any lost profits or reasonable royalty award (whichever measure of damages has been applied in the legal proceeding or settlement thereof); and
(d) the balance, if any, will be divided on a pro rata basis between the parties according to their respective percentage contributions to the total documented cost and expense of the proceeding, including each party’s reasonable
attorneys’ fees and including the total amount of DUKE RUNNING ROYALTIES to DUKE, if any, deducted by COMPANY under the preceding sentence. 

  

	 	8.05	 In the event COMPANY does not undertake action to prevent the infringing activity within [***] ([***]) [***] of
having been made aware and notified thereof, DUKE shall have the right, but not the obligation, to prosecute at its own expense any such infringements of the DUKE PATENT RIGHTS and, in furtherance of such right, DUKE may, subject to the express,
prior written approval of COMPANY (such approval not to be unreasonably withheld or delayed) use the name of COMPANY as a party plaintiff in any such suit without expense to COMPANY. The total cost of any such infringement action commenced or
defended solely by DUKE shall be borne by DUKE. Any recovery of damages by DUKE for any infringement shall be applied first in satisfaction of any unreimbursed expenses and attorneys’ fees of DUKE relating to the suit, and second toward
reimbursement of COMPANY’s reasonable expenses, including reasonable attorneys’ fees, relating to the suit. Any balance remaining from such recovery shall be distributed between COMPANY and DUKE with DUKE receiving [***] ([***]) and
COMPANY receiving [***] ([***]). 

  

	 	8.06	 In any infringement suit instituted by either party to enforce the DUKE PATENT RIGHTS, the other party hereto
shall, at the request and expense of the party initiating such suit, reasonably cooperate in all respects and, to the extent reasonably possible, have its employees testify when requested and make available relevant records, papers, information,
samples, specimens, and the like. 

  
 26 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	8.07	 COMPANY has the sole right in accordance with the terms and conditions of this AGREEMENT to sublicense any DUKE
PATENT RIGHTS to an alleged infringer under the DUKE PATENT RIGHTS in order to avoid or settle claims of infringement in the future. 

  

	 	8.08	 Any of the foregoing notwithstanding, if at any time during the term of this AGREEMENT any of the DUKE PATENT
RIGHTS are held invalid or unenforceable in a decision which is not appealable or is not appealed within the time allowed, COMPANY shall have no further obligations to DUKE with respect to its future use or sale of any LICENSED PRODUCT, LICENSED
PROCESS and/or LICENSED SERVICE covered solely by such DUKE PATENT RIGHTS, including the obligation of paying DUKE RUNNING ROYALTIES. For avoidance of doubt, it is understood and agreed that in such event, COMPANY shall not have any damage
claim or any claim for refund or reimbursement against DUKE for any amounts previously paid to DUKE under this AGREEMENT, including, but not limited to, the issuance of the DUKE STOCK. 

ARTICLE 9 - GOVERNMENT CLEARANCE, PUBLICATION, EXPORT 
  

	 	9.01	 Insofar as such clearance is required, COMPANY agrees to use its best efforts to have the LICENSED PRODUCTS
cleared for marketing in those countries in which COMPANY intends to sell LICENSED PRODUCTS by the responsible government agencies requiring such clearance. To accomplish said clearances at the earliest possible date, COMPANY agrees to file or have
filed any necessary data with said government agencies as quickly as is commercially reasonable. 

  

	 	9.02	 It is understood and agreed that, notwithstanding anything to the contrary in this AGREEMENT, the right of
publication/public disclosure of the DUKE PATENT RIGHTS shall reside in the INVENTORS, faculty, staff, and students of DUKE provided that, for a period of [***] ([***]) [***] from the EFFECTIVE DATE, if any proposed publication or public disclosure
by the appertaining INVENTORS includes information generated at DUKE respecting any of the INVENTIONS claimed in the DUKE PATENT RIGHTS, then DUKE, via Dr. Tedder, shall give COMPANY written notice at least [***] ([***]) [***] prior to such
publication/public disclosure in order to afford COMPANY the opportunity to file or have filed, at its expense, appropriate patent applications to the extent, but only to the extent, that such patent application fall within the scope of DUKE PATENT
RIGHTS. COMPANY may publish the results of research conducted by COMPANY, provided that such publications do not reveal the results of research conducted at DUKE without the prior written consent of those who performed such research at DUKE.

  
 27 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	9.03	 This AGREEMENT is subject to all of the United States laws and regulations controlling the export of technical
data, computer software, laboratory prototypes and other commodities and technology. It is understood that DUKE is subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and
other commodities (including the Arms Export Control Act, as amended and the Export Administration Act of 1979), and that its obligations hereunder are contingent on compliance with applicable United States export laws and regulations. The transfer
of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by COMPANY that COMPANY shall not export data or commodities to certain foreign countries without
prior approval of such agency. DUKE neither represents that a license shall not be required nor that, if required, it shall be issued. 

ARTICLE 10 - DURATION AND TERMINATION 
  

	 	10.01	 This AGREEMENT shall become effective upon the EFFECTIVE DATE, and unless sooner terminated in accordance with
any of the provisions herein, shall remain in full force and effect for the life of the last-to-expire of the patents included in the DUKE PATENT RIGHTS.

  

	 	10.02	 COMPANY may terminate this AGREEMENT by giving DUKE written notice at least three (3) months prior to the
effective date of such termination. It is understood that COMPANY shall remain responsible for the timely payment of all amounts due DUKE under this AGREEMENT through the effective date of such termination. 

 

	 	10.03	 Either party may immediately terminate this AGREEMENT upon any judgment or conviction by a court of competent
jurisdiction holding that the other party has committed fraud, willful misconduct, or illegal conduct of the other party, in all such cases with respect to the subject matter of this AGREEMENT, upon written notice of same to that other party.

  

	 	10.04	 If either party fails to fulfill any of its material obligations under this AGREEMENT including, but not
limited to, lack of payment, the non-breaching party may terminate this AGREEMENT, upon written notice to the breaching party, as provided below. Such notice must contain a full description of the event or
occurrence constituting a material breach of the AGREEMENT. The party receiving notice of the material breach will have the opportunity to cure that breach within the applicable time period, as follows: (a) with respect to a breach of a payment
obligation, within [***] ([***]) [***] of receipt of notice, or (b) with respect to a breach of an obligation other than a payment obligation, within [***] ([***]) [***] of receipt of such notice. If the breach is not cured within the
applicable cure period, the termination will be effective as of the next day following the expiration of such cure period. A party’s right to cure a material breach of this AGREEMENT pursuant to this Section 10.04 will apply only to the
first three (3) material breaches occurring within the same twenty-four (24) month period properly noticed under the terms of this AGREEMENT, regardless of the nature of those material breaches. Any subsequent material breach by that party
will entitle the nonbreaching party to terminate this AGREEMENT upon receipt of notice by the breaching party, where such notice must contain a full description of the event or occurrence constituting a material breach of this AGREEMENT.

  
 28 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	10.05	 If during the term of this AGREEMENT, COMPANY shall (a) voluntarily declare or seek protection under
bankruptcy or insolvency laws, (b) have an involuntary petition in bankruptcy filed against it, which petition is not dismissed within [***] ([***]) [***] following its filing, (c) have its business placed in the hands of a receiver or
trustee and the appointment of such receiver or trustee if not dissolved within [***] ([***]) [***], or if (d) COMPANY shall cease to exist as an active business, then this AGREEMENT shall immediately terminate. 

 

	 	10.06	 Notwithstanding anything to the contrary in this AGREEMENT, neither the expiration nor any termination of this
AGREEMENT shall remove any financial obligations to DUKE which COMPANY incurred under this AGREEMENT prior to or as of the effective date of any expiration or termination. 

 

	 	10.07	 All SUBLICENSES will be assigned to and assumed DUKE in the event the AGREEMENT is terminated.

  

	 	10.08	 On or before the effective date of any expiration or termination of this AGREEMENT, COMPANY shall cease the
manufacture, use, practice, lease, and sale, offering, distribution, and other commercialization of LICENSED PRODUCTS, LICENSED PROCESSES, and LICENSED SERVICES. For avoidance of doubt, any SUBLICENSE in existence as of the effective date of any
termination shall be unaffected by such termination other than the assignment and assumption provided for in Section 10.07. 

  

	 	10.09	 Within [***] ([***]) [***] of any expiration or termination of this AGREEMENT, COMPANY shall (i) return to
DUKE or destroy, as directed by DUKE, all information, data, and any relevant materials provided to COMPANY during the term of this AGREEMENT (including, but not limited to, DUKE MATERIAL and KNOW-HOW), other
than any of the foregoing items in the possession of a SUBLICENSEE, and (ii) destroy all LICENSED PRODUCTS (other than LICENSED PRODUCTS in the possession of any SUBLICENSEE or customer) in a safe and legal manner. Further, COMPANY within such
[***] ([***]) [***] period shall provide DUKE with a written statement signed by an authorized representative of COMPANY certifying the destruction of all LICENSED PRODUCTS (other than LICENSED PRODUCTS in the possession of any SUBLICENSEE or
customer) in a safe and legal manner, as well as the destruction of all said information, data, and relevant materials (including, but not limited to, DUKE MATERIAL and all KNOW-HOW), other than any of the
foregoing items in the possession of a SUBLICENSEE, if such instructions for destruction are given by DUKE. 

  
 29 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ARTICLE 11 - CONFIDENTIALITY 

 

	 	11.01	 DUKE and COMPANY each agree to treat any CONFIDENTIAL INFORMATION disclosed to it by the other party under this
AGREEMENT with reasonable care and to avoid disclosure of such CONFIDENTIAL INFORMATION to any other person, firm or corporation, except AFFILIATES bound by the obligations of confidentiality and restricted use set forth in this Article 11, and
either party shall be liable for unauthorized disclosure or failure to exercise such reasonable care. Further, the receiving party will not use the disclosing party’s CONFIDENTIAL INFORMATION other than for the benefit of the parties hereto and
in connection with such receiving party’s performance of its obligations under this AGREEMENT. These obligations of non-disclosure and restricted use shall remain in effect for each subject disclosure of
CONFIDENTIAL INFORMATION for a period of time of [***] ([***]) [***] from such disclosure; however, neither party shall have an obligation, with respect to CONFIDENTIAL INFORMATION disclosed to it, or any part thereof, which: 

 

	 	(a)	 is already known to the receiving party at the time of the disclosure; 

 

	 	(b)	 becomes publicly known without the wrongful act or breach of this AGREEMENT by the receiving party;

  

	 	(c)	 is rightfully received by the receiving party from a THIRD PARTY on a
non-confidential basis; 

  

	 	(d)	 is subsequently and independently developed by employees of the receiving party who had no knowledge of the
CONFIDENTIAL INFORMATION, as verified by written records; 

  

	 	(e)	 is approved for release by prior written authorization of the party disclosing the CONFIDENTIAL INFORMATION; or

  

	 	(f)	 is disclosed pursuant to any judicial or government request, requirement or order, provided that the party so
disclosing takes reasonable steps to provide the other party sufficient prior notice in order to contest such request, requirement or order and provided and provided that such disclosed CONFIDENTIAL INFORMATION otherwise remains subject to the
obligations of confidentiality set forth in this Article 11. 

 If either party discloses CONFIDENTIAL INFORMATION directly
to Dr. Thomas Tedder, such CONFIDENTIAL INFORMATION shall not be deemed to have been received by the other party. 
  

	 	11.02	 DUKE and COMPANY agree that any information to be treated as CONFIDENTIAL INFORMATION under this Article 11
must be disclosed in writing or other tangible medium and must be clearly marked “CONFIDENTIAL”. CONFIDENTIAL INFORMATION disclosed orally must be identified as “CONFIDENTIAL” at the time of the oral disclosure and thereafter
summarized and reduced to writing or other tangible medium, marked “CONFIDENTIAL”, and communicated to the other party within [***] ([***]) [***] of such disclosure. For avoidance of doubt, electronic transmissions of CONFIDENTIAL
INFORMATION shall be deemed to have been disclosed in a tangible medium. 

  
 30 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	11.03	 Notwithstanding the foregoing, COMPANY shall have the right to use and disclose any CONFIDENTIAL INFORMATION
related to the DUKE PATENT RIGHTS to investors, prospective investors, employees, consultants and agents with a need to know, collaborators, prospective collaborators and other THIRD PARTIES in the chain of manufacturing and distribution provided
that COMPANY obtains from such parties written confidentiality agreements, the provisions of which are at least as restrictive and protective of DUKE’s CONFIDENTIAL INFORMATION as those provided in this Article 11. 

 

	 	11.04	 Subject to the exceptions set forth in Section 11.01, but not notwithstanding anything else to the
contrary in this AGREEMENT, all information relating to filing, prosecution, maintenance, defense, infringement, and the like regarding the DUKE PATENT RIGHTS (no matter how disclosed), shall be considered CONFIDENTIAL INFORMATION of DUKE and
subject to the obligations of restricted use and non-disclosure set forth in this Article 11. 

ARTICLE 12 - NOTICES 
  

	 	12.01	 It shall be a sufficient giving of any notice, request, report, statement, disclosure or other communication
hereunder if the party giving the same shall 

  

	 	(a)	 hand deliver such communication; or 

 

	 	(b)	 mail such a communication, postage prepaid, first class, certified mail, return receipt requested; or

  

	 	(c)	 send such communication, shipping prepaid by national/international courier service guaranteeing next-business-day delivery 

 to the party to receive such communication at the address
given below or as given in Section 3.07, in the case of payments and/or reports due in accordance with Sections 3.01, 3.06, 4.01, 4.02, 5.01, 5.02, 5.03, 6.02, and 6.03 or such other address as may hereafter be designated by notice in writing
by the appertaining party. 
  

					
		 	DUKE	  	COMPANY
			
	                	 	For delivery via the U.S. Postal Service	  	
			
		 	 University Office of Science and Technology

Duke University
 Attn: Agreement Coordinator

Box 90083
	  	 Cellective Therapeutics, Inc.
 4819 Emperor
Boulevard, Suite 400
 Durham, NC 27703 USA
  

Attn: President

		 	Durham, NC 27708 USA	  	

  
 31 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

					
		
	                 

	 	 For delivery via nationally/internationally

recognized courier service

			
		 	 Office of Science and Technology
 Duke
University
 Attn: Agreement Coordinator
 2020 West Main Street,
Suite 10
 Durham, NC 27705 USA
	  	 Cellective Therapeutics, Inc.
 4819 Emperor
Boulevard, Suite 400
 Durham, NC 27703 USA
  

Attn: President

			
		 	 cc:     (if of a legal nature)

Office of University Counsel
 Duke University

2400 Pratt Street, Suite 4000
 Durham, NC 27710 USA
	  	  
 M. Christopher Bolen, Esq.

Womble Carlyle Sandridge & Rice
 2530 Meridian Pkwy,
Suite 400
 Durham, NC 27713 USA

  

	 	12.02	 The date of giving any such notice, request, report, statement, disclosure or other communications, and the
date of making any payment hereunder required (provided such payment is received), shall be the actual date of receipt. 

 ARTICLE 13 -
TRANSFER OF DUKE MATERIALS AND KNOW-HOW TO COMPANY 
  

	 	13.01	 Transfer to COMPANY of DUKE MATERIALS and/or KNOW-HOW of a tangible
biological and/or chemical nature (that is, not KNOW-HOW in a written or electronic form) shall be transferred subject to the terms set forth in this Section 13 and elsewhere in this AGREEMENT (including,
but not limited to the MASTER DUKE TO COMPANY MATERIAL TRANSFER AGREEMENT set forth in APPENDIX D appended to this AGREEMENT) and shall not be transferred to COMPANY until after the full execution by appropriate and authorized representatives of the
respective parties of an appertaining material transfer record form (a sample form of which is attached in EXHIBIT I of APPENDIX D; hereinafter such form referred to as “MATERIAL TRANSFER RECORD FORM”) which expressly identifies all of the
subject DUKE MATERIALS and/or KNOW-HOW to be transferred at that point in time. 

  

	 	13.02	 To defray the costs associated with the transfer of DUKE MATERIALS and
KNOW-HOW to COMPANY, COMPANY shall make the following non-refundable, non-creditable payments to Dr. Thomas Tedder’s
laboratory at DUKE: (i) [***] (US$[***]) to be received by Dr. Tedder’s laboratory at DUKE in [***] ([***]) [***] installments of [***] ($[***]) each within [***] ([***]) [***] following the last day of each of the [***] ([***]) [***]
following the EFFECTIVE DATE; (ii) [***] (US$[***]) to be received by Dr. Tedder’s laboratory at DUKE in [***] ([***]) [***] installments of [***] ($[***]) each within [***] ([***]) [***] following the last day of each of the [***] ([***])
[***] following the first 

  
 32 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
anniversary of the EFFECTIVE DATE; and (iii) [***] (US$[***]) to be received by Dr. Tedder’s laboratory at DUKE in [***] ([***]) [***] of [***] ($[***]) each within [***] ([***]) [***]
following the last day of each of the [***] ([***]) [***] following the second anniversary of the EFFECTIVE DATE. Each such payment shall be in check form made payable to “Duke University,” shall reference this AGREEMENT, and shall be
delivered to Dr. Thomas Tedder, 353 Jones Building, Research Drive, Box 3010, DUMC, Duke University, Durham, NC 27710. If Dr. Tedder’s employment with DUKE terminates prior to the due date for payments under clause (i), (ii) and/or
(iii) of this Section 13.02, then COMPANY shall have no further obligation under this Section 13.02 (i), (ii) and/or (iii) (as the case may be) for payments due after the effective date of Dr. Tedder’s termination of
employment with DUKE. 

 ARTICLE 14 - ASSIGNMENT 
  

	 	14.01	 This AGREEMENT shall be binding upon and inure to the benefit of the respective successors and assigns of the
parties hereto. Neither party may assign its rights in this AGREEMENT without approval by the other party, such approval not to be unreasonably withheld, provided, however, that such consent shall not be required in connection with a
transfer or assignment resulting from the acquisition of substantially all of the assets of COMPANY by a THIRD PARTY whether by merger, consolidation, sale of assets, or otherwise. 

ARTICLE 15 - INDEMNITY, INSURANCE, REPRESENTATIONS, STATUS 
  

	 	15.01	 DUKE, and its trustees, officers, employees, faculty members, students, and agents will be indemnified,
defended by counsel reasonably acceptable to DUKE, and held harmless by COMPANY and appertaining SUBLICENSEES, as the case may be, from and against any claim, liability, cost, expense, damage, deficiency, loss or obligation, of any kind or nature
(including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “CLAIMS”) based upon, arising out of, or otherwise relating to this AGREEMENT including, but not limited to,
(i) any action relating to product liability, and (ii) any CLAIM that a LICENSED PRODUCT, and/or LICENSED SERVICE and/or practice of any of the DUKE PATENT RIGHTS and/or KNOW-HOW infringes the
intellectual property of a THIRD PARTY. However, the foregoing indemnity shall not apply to CLAIMS to the extent that they are (y) caused by the negligence or willful misconduct of DUKE, DUKE employees, DUKE faculty members, students, and/or
agents acting solely within the performance of their respective responsibilities at DUKE, and/or (z) acts of God or other events for which COMPANY (and/or SUBLICENSEE(S), as the case may be) has no control. 

  
 33 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	15.02	 COMPANY will purchase and maintain in effect, at its sole expense, with reputable insurance companies,
appropriate insurance policies, including, but not limited to a policy of product liability insurance and a policy of general commercial liability insurance, in such amounts as is reasonably sufficient and commercially reasonable to protect against
its liability under Section 15.01 above. Further, COMPANY will require that each SUBLICENSEE, purchase and maintain in effect, at its sole expense, with reputable insurance companies, appropriate insurance policies, including, but not limited
to a policy of product liability insurance and a policy of general liability insurance, in such amounts as is reasonably sufficient and commercially reasonable to protect against their respective liability as regards Section 15.01 above. It is
understood and agreed that COMPANY and/or SUBLICENSEES (as the case may be) shall not be required to possess product liability insurance under this Section 15.02 until the first of the following to occur as regards COMPANY and/or appertaining
SUBLICENSEES (i) commencement of clinical trials of a LICENSED PRODUCT; or (ii) commencement of sale, lease, or provision of LICENSED PRODUCTS (including, but not limited to provision of LICENSED SERVICES in connection with a clinical
trial). DUKE shall have the right to ascertain from time to time that any required coverage under this Section 15.02 exists, such right to be exercised by DUKE in a reasonable manner. 

 

	 	15.03	 DUKE represents and warrants to COMPANY that, to the best knowledge of the DUKE University Office of Science
and Technology, (i) DUKE has not received any notice of infringement from any THIRD PARTY relating to the INVENTIONS or the DUKE PATENT RIGHTS; (ii) no claim, suit or action has been made, brought or threatened by any THIRD PARTY with
respect to the INVENTIONS or the DUKE PATENT RIGHTS, and there is no basis for any such claim, suit or action; (iii) DUKE has the authority to enter into this AGREEMENT; (iv) DUKE has the authority to grant the LICENSES herein without the
consent of any THIRD PARTY; (v) the execution, delivery and performance of this AGREEMENT by DUKE does not violate any covenant or agreement to which DUKE is a party or by which it is bound; and (vi) except for rights owned by The Regents
of the University of California in DUKE University Office of Science and Technology File #2087 INVENTION, DUKE owns all right, title, and interest, in and to the INVENTIONS and the DUKE PATENT RIGHTS. 

 

	 	15.04	 EXCEPT AS EXPRESSLY SET FORTH IN SECTION 15.03, DUKE MAKES NO REPRESENTATIONS NOR EXTENDS ANY WARRANTIES OF ANY
KIND. IN PARTICULAR, THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THE USE OF THE DUKE PATENT RIGHTS AND/OR KNOW-HOW DOES NOT INFRINGE ANY PATENT,
COPYRIGHT, TRADEMARK OR OTHER RIGHTS. IN ADDITION, NOTHING IN THIS AGREEMENT SHALL BE DEEMED TO BE A REPRESENTATION OR WARRANTY BY DUKE OF THE VALIDITY OF ANY OF THE DUKE PATENT RIGHTS OR THE ACCURACY, SAFETY, EFFICACY, OR USEFULNESS, FOR ANY
PURPOSE, OF THE DUKE PATENT RIGHTS OR KNOW-HOW. DUKE SHALL HAVE NO OBLIGATION, EXPRESS OR IMPLIED, TO SUPERVISE, MONITOR, REVIEW OR OTHERWISE ASSUME RESPONSIBILITY FOR THE

  
 34 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
PRODUCTION, MANUFACTURE, TESTING, MARKETING OR SALE OF ANY LICENSED PRODUCT. (FOR AVOIDANCE OF DOUBT, IT IS UNDERSTOOD AND AGREED THAT ANY SUCH ACTIVITY DESCRIBED IN THE PRECEDING SENTENCE BY ONE
OR MORE OF THE INVENTORS OR ANY OTHER DUKE TRUSTEE, FACULTY MEMBER, EMPLOYEE, STUDENT, AND/OR AGENT SHALL BE DEEMED TO BE OUTSIDE THEIR RESPECTIVE CAPACITY AS A DUKE TRUSTEE, FACULTY MEMBER, EMPLOYEE, STUDENT, AND/OR AGENT, AS THE CASE MAY BE.)
FURTHER, DUKE SHALL HAVE NO LIABILITY WHATSOEVER TO COMPANY, ITS AFFILIATES, SUBLICENSEES, OR ANY THIRD PARTIES FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR ASSERTED AGAINST, OR ANY
OTHER LIABILITY INCURRED BY OR IMPOSED UPON COMPANY OR ANY OTHER PERSON OR ENTITY, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM: 

  

	 	(a)	 the production, use, practice, offering, lease, or sale of any LICENSED PRODUCT and/or LICENSED SERVICES;

  

	 	(b)	 the use of the DUKE PATENT RIGHTS, DUKE MATERIALS, and/or KNOW-HOW; or

  

	 	(c)	 any advertising or other promotional activities with respect to any of the foregoing. 

 

	 	15.05	 Neither party hereto is an agent of the other party for any purpose whatsoever. 

ARTICLE 16 - USE OF A PARTY’S NAME 
  

	 	16.01	 Neither party will, without the prior written consent of the other party: 

 

	 	(a)	 use in any publication, advertising, publicity, press release, promotional activity or otherwise, any
trade-name, personal name, trademark, trade device, service mark, symbol, image, icon, or any abbreviation, contraction or simulation thereof owned by the other party; 

 

	 	(b)	 use the name or image of any employee, faculty member, student, or agent of the other party in any publication,
publicity, advertising, press release, promotional activity or otherwise; or 

  

	 	(c)	 represent, either directly or indirectly, that any product or service of the other party is a product or
service of the representing party or that it is made in accordance with, or utilizes the information or documents, of the other party. 

Notwithstanding the foregoing, COMPANY will be permitted to use DUKE’s name and the name of Dr. Thomas Tedder (provided that COMPANY
shall first have secured written permission of Dr. Tedder to use his name) in connection with: 

  
 35 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
(i) COMPANY’s business plan; (ii) in other investor-related documents to the extent required by applicable law; and (iii) information directed to prospective SUBLICENSEES or
strategic alliance partners. COMPANY may also state that the LICENSES have been granted to COMPANY by DUKE. DUKE shall not prevent its employees from consenting to use their respective names, so long as such use does not represent to be endorsement
by DUKE or an official DUKE position. COMPANY shall not represent that any product is endorsed by Duke. 
 ARTICLE 17 - SEVERANCE AND WAIVER 

 

	 	17.01	 Each clause of this AGREEMENT is a distinct and severable clause and if any clause is deemed illegal, void or
unenforceable, the validity, legality or enforceability of any other clause or portion of this AGREEMENT will not be affected thereby. 

  

	 	17.02	 No waiver of this AGREEMENT, or any of the provisions herein contained is valid unless made in writing and
signed by a duly authorized representative of each party. The failure of a party in any instance to insist upon the strict performance of the terms of this AGREEMENT will not be construed to be a waiver or relinquishment of any of the terms of this
AGREEMENT, either at the time of the party’s failure to insist upon strict performance or at any time in the future, and such terms will continue in full force and effect. 

ARTICLE 18 - TITLES 
  

	 	18.01	 All titles and article headings contained in this AGREEMENT are inserted only as a matter of convenience and
reference. They do not define, limit, extend or describe the scope of this AGREEMENT or the intent of any of its provisions. 

 ARTICLE
19 - SURVIVAL OF TERMS 
  

	 	19.01	 The provisions of Sections 2.04, 3.03, 3.04, 3.05, 3.06, 3.07, 5.01, .5.03 (as regards obligations for reports
and payments due to DUKE for activities occurring during the term of this AGREEMENT), 9.03, 10.06, 10.07, 10.08 (last sentence), 10.09, and Articles 1, 7, 8 (to the extent, but only to the extent, that such infringement occurs during the term of
this AGREEMENT and excluding Section 8.06 which shall only apply during the term of this AGREEMENT), 11, 12, 14, 15, 16, 17, 18, 19, 20, and 21 shall survive the expiration or termination of this AGREEMENT. 

ARTICLE 20 - GOVERNING LAW 
  

	 	20.01	 This AGREEMENT shall be construed as having been entered into in the State of North Carolina and shall be
interpreted in accordance with and its performance governed by the laws of the State of North Carolina, without regard to any choice-of-law or conflict-of-law provision that would dictate the application of the law of another jurisdiction. Notwithstanding the foregoing, questions affecting the construction and effect
of any patent in DUKE PATENT RIGHTS shall be determined by the law of the country in which the patent was granted. 

  
 36 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ARTICLE 21 - ENTIRE UNDERSTANDING 

 

	 	21.01	 This AGREEMENT, together with the recitals and all Appendices and Exhibits (all of which are incorporated
herein by reference), represent the entire understanding between the parties, and supersede all other agreements, express or implied, between the parties concerning the subject matter hereof, including, without limitation, that certain Confidential
Disclosure Agreement, dated effective December 29, 2003, by and between DUKE and COMPANY (the “PRIOR CDA”); provided, however, that all confidential disclosures made by the parties to each other pursuant to the PRIOR CDA
prior to the EFFECTIVE DATE of this AGREEMENT shall be governed by the provisions of Section 1.04 and Article 11 of this AGREEMENT from and after such EFFECTIVE DATE. This AGREEMENT shall not be subject to any change or modification except by
the execution of a written instrument subscribed to by the parties hereto. If there is any conflict between this AGREEMENT and the MASTER DUKE TO COMPANY MATERIAL TRANSFER AGREEMENT, this AGREEMENT will govern. 

ARTICLE 22 - COUNTERPARTS 
  

	 	22.01	 This AGREEMENT may be executed in one or more counterparts, each of which shall be deemed an original and all
of which, taken together, shall constitute the same instrument. For purposes of this AGREEMENT, a faxed signature shall be effective and treated as an original signature. 

[The balance of this page intentionally left blank.] 

  
 37 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 IN WITNESS WHEREOF, the parties hereto have executed this AGREEMENT on the dates set
forth below. 
  

									
		 	DUKE UNIVERSITY	 		 		 	CELLECTIVE THERAPEUTICS, INC.
					
		 	By: /s/ [***]	 		 		 	By: /s/ [***]
		 	 [***]
 [***]

[***]
	 		 		 	 [***]
 [***]

					
		 	Date: 9-17-04	 		 		 	Date: 9-21-04
					
		 	Read and Understood	 		 		 	
					
		 	By: /s/ [***]	 		 		 	
		 	[***]	 		 		 	
					
		 	Date: 09-17-04	 		 		 	
					
		 	By: /s/ [***]	 		 		 	
		 	[***]	 		 		 	
					
		 	Date: 09-17-04	 		 		 	
					
		 	By: /s/ [***]	 		 		 	
		 	[***]	 		 		 	
					
		 	Date: 09-17-04	 		 		 	

  
 38 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 APPENDICES 

APPENDIX A - DUKE PATENT RIGHTS 
 APPENDIX B - SAMPLE MATERIAL
TRANSFER AGREEMENTS 
 APPENDIX C - COMPANY PERFORMANCE MILESTONE SCHEDULE 

APPENDIX D - ROYALTY REPORT FORM (SAMPLE) 
 APPENDIX E - MASTER
DUKE TO COMPANY MATERIAL TRANSFER AGREEMENT 

  
 39 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 APPENDIX A 

DUKE PATENT RIGHTS 
  

	1.	 [***]; 

  

	2.	 [***]; 

  

	3.	 [***]; and 

  

	4.	 [***]. 

  
 40 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 APPENDIX B 

SAMPLE MATERIAL TRANSFER AGREEMENTS 

SAMPLE 1 
 TO
BE USED WHEN MATERIAL WAS ORIGINALLY GENERATED IN [***] 
 LABORATORY AT DANA-FARBER CANCER INSTITUTE 

MATERIAL TRANSFER AGREEMENT 

Duke University (“Duke”) 

Durham, NC 27710 
 to

 [Recipient Institution Name Here] 

[City, State, and Country where Recipient Institution Located Here] (“Recipient Institution”) 

Definitions: 
 Recipient Institution’s
Scientist:
                                         
                                         
   
 Original Material:
                                         
                                         
                       

Progeny: Unmodified descendant from the Original Material, such as cell from cell, or organism from organism. 

Unmodified Derivatives: Substances created by Recipient Institution which constitute an important unmodified
functional sub-unit or expression product of the Original Material, e.g., subclones of unmodified cell lines, purified or fractionated sub-sets of the Original Material
such as novel plasmids or vectors, proteins expressed by DNA or RNA, antibodies secreted by a hybridoma. 

Material: Original Material plus Progeny and Unmodified Derivatives. 

Modifications: Substances created by Recipient Institution which contain/incorporate any form of the Material
(Original Material, Progeny or Unmodified Derivatives). 
 Information: All information disclosed to Recipient Institution by Duke relating to the
Material and/or Modifications. 
 Research Purpose:
                                         
                                         
                       
  

                          
                                         
                                         
                             

  
 41 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Terms and Conditions of this Agreement: 

1. (a) The Material, which is the subject of one or more agreements with Cellective Therapeutics, Inc., a corporation organized under the laws of Delaware and
having a place of business in Durham, North Carolina (“Licensee”), is and remains the property of the Dana-Farber Cancer Institute, Inc. (“DFCI”) (subject to certain rights granted to Licensee) and is to be used by Recipient
Institution solely for a non-commercial Research Purpose. 
 (b) Except as is mutually agreed upon
in writing in advance by DFCI, Duke and Recipient Institution, the Material is to be used by Recipient Institution at Recipient Institution’s institutional facilities only, and only under the direction of Recipient Institution’s Scientist.

 (c) Except as set forth in Paragraph 4 and as claimed in [***] and [***], [***], and [***] owned by DFCI, neither DFCI nor Duke claims
ownership of substances and Modifications produced as a result of Recipient Institution’s research with the Material that are not included in the definition of Material above. 

(d) Except as expressly provided in this Agreement, no rights are provided to Recipient Institution under any patent applications, patents,
trade secrets or other proprietary rights of DFCI and/or Duke. In particular, no rights are provided to use the Material or Modifications for profit-making or commercial purposes, such as sale; use in manufacturing; use in drug screening,
evaluation, or design programs; or provision of a commercial service based upon the Material or Modifications. 
 (e) If Recipient
Institution desires to use the Material or Modifications for such profit-making or commercial purposes, Recipient Institution agrees that it must first negotiate a license or other appropriate agreement with DFCI and/or Duke and/or Licensee, as the
case may be, and it is further understood by Recipient Institution that neither DFCI nor Duke shall have any obligation to enter into such a license or agreement and in fact may grant exclusive or
non-exclusive commercial licenses to others. 
 (f) Recipient Institution represents that research
with the Material and/or Modifications will not be subject to the terms of any consultant, option, license, or sponsored research agreement in which a third party (other than the government) gains rights to the research results and/or the
intellectual property arising from research with the Material and/or Modifications without the express, prior written approval of DFCI, Duke or Licensee. 

2. Recipient Institution’s Scientist agrees not to transfer the Material or Modifications to anyone who does not work under his or her direct supervision
at Recipient Institution without the express, prior written consent of DFCI and Duke. To the extent supplies are available, DFCI and/or Duke will make the Material available under a material transfer agreement substantially similar to this Agreement
upon request from appropriate scientists at non-profit or governmental institutions for the purpose of replicating Recipient Institution’s Scientist’s research. 

3. Recipient Institution agrees to hold confidential all Information except as such Information: (a) can be demonstrated was known by the Recipient
Institution at the time of disclosure; (b) becomes part of the public domain, except by breach of this Agreement by Recipient Institution; (c) is rightfully received by Recipient Institution from a third party without an obligation of
confidence to DFCI, Duke or Licensee; or (d) is independently developed by Recipient Institution’s personnel who have not had access to Information, Material or Modifications as demonstrated by competent written proof. Recipient
Institution’s obligations of nondisclosure of Information shall terminate [***] ([***]) [***] from the date that this Agreement is signed by Duke. 

  
 42 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
4. If Recipient Institution’s research results in an invention, a new use, or a product based on, containing, or relating to the Material or Modifications (collectively referred to as
“Invention”), Recipient Institution agrees promptly to disclose the Invention to Duke and DFCI on a confidential basis. Inventorship shall be determined in accordance with U.S. patent law (whether or not patentable) and ownership shall
reflect inventorship. In the case of a jointly owned invention between Duke and the Recipient Institution or among Duke, DFCI and Recipient Institution (“Joint Invention”), the appertaining parties agree to negotiate a joint invention
agreement which shall provide for fair and equitable sharing of patent costs, income, and invention management responsibilities based on the respective parties’ contributions to the Joint Invention. If Recipient Institution decides not to
pursue the further development of a joint Invention hereunder, Duke and/or DFCI may elect to pursue the patenting or commercial development of said Joint Invention with third parties. If either Recipient Institution or Duke or DFCI is the sole
inventor of any Invention, that party shall be free to dispose of such Invention as it sees fit. However, notwithstanding the foregoing, Duke and DFCI shall each have the right to use for its own respective
non-profit research and teaching purposes any Inventions developed through use of the Material and/or Modifications under this Agreement without payment of license or royalty fees. 

5. Recipient Institution’s Scientist agrees to provide appropriate acknowledgment of DFCI and Duke as the source of the Material in all publications and
presentations based on use of the Material and/or Modifications, and agrees to furnish Duke with a courtesy copy of all public disclosures of results of research using the Materials and Modifications. 

6. Any Material delivered pursuant to this Agreement is understood to be experimental in nature, and NEITHER DUKE NOR DFCI MAKES ANY REPRESENTATIONS NOR
EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL AND/OR MODIFICATIONS WILL NOT INFRINGE ANY PATENT,
COPYRIGHT, TRADEMARK, OR OTHER RIGHTS, OR THAT THE MATERIAL AND/OR MODIFICATIONS WILL NOT POSE A SAFETY OR HEALTH RISK. 
 7. Recipient Institution agrees
to defend, indemnify, and hold harmless Duke and DFCI from any loss, claim, damage, or liability, of any kind whatsoever, which may arise from Recipient Institution’s receipt, use, storage or disposal of the Material and/or Modifications, and
Recipient Institution assumes liability for damages which may arise from its receipt, use, storage or disposal of the Material and/or Modifications. 
 8.
In no event shall the Material and/or Modifications be used in human beings (including for diagnostic purposes) except as is mutually agreed upon in writing in advance by DFCI, Duke and Recipient Institution and further provided, that any other
research involving the Material (including but not limited to research involving the use of animals and recombinant DNA) shall be conducted in accordance with all federal, state, local and other laws, regulations, and ordinances governing such
research including applicable NIH guidelines. 

  
 43 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 9. Notices or other correspondence required by this Agreement shall be sent via national/international
courier service to both Duke and DFCI at the following addresses, respectively: 
  

			
	 As to Duke:
	  	As to DFCI:
	 Office of Science and Technology

M454 Davison Building
 Box
3664, DUMC
 Duke University

Durham, NC 27710 USA

Attn.:
	  	 Sr. Vice President for Research
 Dana-Farber
Cancer Institute
 44 Binney Street
 Boston, MA
02115

 10.   (a) Except as mutually agreed upon in writing by DFCI, Duke and Recipient Institution, this Agreement will
terminate on the earliest of the following dates: (1) on completion of Recipient Institution’s proposed research studies with the Material, or (2) on [***] ([***]) [***] written notice by either party to the other, or (3) [***]
([***]) [***] from the date that this Agreement is signed by Duke. 
 (b) On termination of this Agreement, Recipient Institution will
discontinue its use of the Material and will, upon direction of Duke, return or destroy the Material. Recipient Institution will also either destroy any Modifications or remain bound by the terms of this Agreement as they apply to such
Modifications. 
 (c) Paragraphs 3, 4, 5, 6, 7, 9, 10(b), 10(c), 12, and 13 shall survive termination. 

11. This Agreement is not assignable without the express, prior written consent of Duke and DFCI. 

12. Should any provision of this Agreement be held unenforceable or in conflict with the law of any jurisdiction, the validity of the remaining provisions
shall not be affected. 
 13. This Agreement contains the entire understanding between the parties relating to the subject matter hereof. No modification or
amendment of any provision of this Agreement shall be binding unless in writing expressly stated to be an amendment or modification and signed by the respective, authorized representative of each party. 

AGREED: 
  

					
	Duke’s Investigator:	 		 	Recipient Institution’s Scientist:
			
	   
	 		 	   

	
[***]                  
                                         
                         (Date)
	 		 	Name      (Date)

  
 44 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

					
	Duke Institutional Approval:	 		 	Recipient Institutional Approval:
			
	   
	 		 	   

	 Name:
 Title:
	 		 	 Name:
 Title: 

  

					
	 Address:
	 	 DUMC Box 3664
 454 Davison Building

Duke University
 Durham, NC 27710
	 	Address:
		 	 Fax #:

E-mail:
	 	 Fax #:

E-mail:

  
 45 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 SAMPLE 2 

TO BE USED WHEN MATERIAL WAS ORIGINALLY GENERATED IN [***] 

LABORATORY AT DUKE UNIVERSITY 

MTA non-profit # _________ 

MATERIAL TRANSFER AGREEMENT 

Duke University 
 Durham,
NC 27708 USA (“Duke”) 
 to 

[Recipient Institution Name Here] 

[City, State, and Country where Recipient Institution Located Here] (“Recipient
Institution”) 
 Definitions: 

Recipient Institution’s Scientist:
                                         
                                         
                                         
                        

Original Material:
                                         
                                         
                                         
                                         
      
  

                       
                                         
                                         
                                         
                                         
                
 Progeny: Unmodified descendant from
the Original Material, such as cell from cell, or organism from organism. 
 Unmodified Derivatives: Substances created by Recipient
Institution which constitute an important unmodified functional sub-unit or expression product of the Original Material, e.g., subclones of unmodified cell lines, purified or fractionated sub-sets of the Original Material such as novel plasmids or vectors, proteins expressed by DNA or RNA, antibodies secreted by a hybridoma. 

Material: Original Material plus Progeny and Unmodified Derivatives. 

Modifications: Substances created by Recipient Institution which contain/incorporate any form of the Material (Original Material,
Progeny or Unmodified Derivatives). 
 Information: All information disclosed to Recipient Institution by Duke relating to the
Material and/or Modifications. 
 Research Purpose:
                                         
                                         
                                         
                                         
        
  

                       
                                         
                                         
                                         
                                         
                  

  
 46 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Terms and Conditions of this Agreement: 

1. (a) The Material, which is the subject of one or more agreements between Duke and Cellective Therapeutics, Inc., a corporation organized under the laws of
Delaware and having a place of business in Durham, North Carolina (“Licensee”), is and remains the property of Duke (subject to certain rights granted to Licensee) and is to be used by Recipient Institution solely for a non-commercial Research Purpose. Material shall be used at Recipient Institution’s institutional facilities only, and only under the direction of Recipient Institution’s Scientist. 

(b) Duke and Licensee do not claim ownership of Modifications produced as a result of Recipient Institution’s research with the material
that are not included in the definition of Material above except as Duke as a co-owner of the Modifications via inventorship; however, Duke shall retain ownership of any form of the Material included therein.

 (c) Except as expressly provided in this Agreement, no rights are provided to Recipient Institution under any patents, patent
applications, trade secrets or other proprietary rights of Duke and/or Licensee. This Agreement does not confer to the Recipient Institution any rights or licenses to use the Material or Modifications for profit-making or commercial purposes, such
as sale; use in manufacturing; provision of a commercial service based upon the Material or Modifications; or use the Material or Modifications as the subject of collaboration or sponsored research agreements under which rights may be granted to a
third party (other than the government). 
 (d) Recipient Institution represents that research with the Material and/or Modifications will
not be subject to the terms of any consultant, option, license, material transfer agreement, sponsored research agreement or any other agreement in which another party (other than the government) gains rights to commercially develop or market the
intellectual property arising from research with the Material and/or Modifications. 
 2. The Recipient Institution’s Scientist shall not transfer the
Material or Modifications to anyone who does not work under his or her direct supervision at Recipient Institution’s institutional facility without the prior written consent of Duke and Licensee. To the extent supplies are available, Duke will
make the Material available under a material transfer agreement substantially identical to this Agreement upon request from appropriate scientists at non-profit or governmental institutions for the purpose of
replicating Recipient Institution’s Scientist’s research. 
 3. Recipient Institution agrees to hold confidential all Information except as such
Information: (a) can be demonstrated was known by the Recipient Institution at the time of disclosure; (b) becomes part of the public domain, except by breach of this Agreement by Recipient Institution; (c) is rightfully received by
Recipient Institution from a third party without an obligation of confidence to Duke or Licensee; or (d) is independently developed by Recipient Institution’s personnel who have not had access to Information, Material or Modifications as
demonstrated by competent written proof. Recipient Institution’s obligations of nondisclosure of Information shall terminate [***] ([***]) [***] from the date that this Agreement is signed by Duke. 

4. (a) If Recipient Institution’s research with Material or Modifications results in an invention (“Invention”), Recipient Institution agrees
to disclose promptly the Invention to both Duke and Licensee on a confidential basis. Inventorship shall be determined in accordance with U.S. patent law (whether or not patentable) and ownership shall reflect inventorship. 

  
 47 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (b) If Recipient Institution decides not to pursue the further development of an Invention
hereunder, Duke and/or Licensee, may elect to pursue the patenting or commercial development of said Invention at their/its own discretion. In the event that Licensee so elects to pursue the patenting or commercial development of such an Invention
then Recipient Institution will have the right to use the subject Invention for its own internal research, education, and/or teaching purposes and for no other purposes. 

(c) Licensee shall have an exclusive, first option to obtain an exclusive, worldwide, royalty-bearing commercial license for Invention,
exercisable for a period of [***] ([***]) [***] from Licensee’s receipt of the disclosure thereof. Upon exercise of such option by Licensee, each owner of such Invention agrees to make good-faith efforts to negotiate an exclusive license
agreement for the Invention with Licensee on reasonable commercial terms. 
 (d) In addition to the rights that Duke may have as a result of
co-ownership of Inventions made jointly with the Recipient Institution, Duke shall also have the right to use for its own internal research, education, and/or teaching purposes, and for no other purposes, any
and all other Inventions developed through use of the Material or Modifications under this Agreement without payment of license or royalty fees. 
 5. This
Agreement shall not be interpreted to prevent publication or other disclosure of results of research using the Material or Modifications. Recipient Institution’s Scientist agrees to provide appropriate acknowledgment of the source of the
Material in all publications and presentations based on use of the Material and/or Modifications. Recipient Institution’s Scientist further agrees to furnish both Duke and Licensee with a copy of the manuscript or abstract disclosing such
results prior to submission thereof to publisher and not less than [***] ([***]) [***] prior to publication/disclosure, for review by Duke and Licensee. Duke and Licensee shall promptly provide Recipient Institution with any comments relating to
said publication or presentation and Recipient Institution may proceed with said publication or presentation with due consideration to Duke and/or Licensee’s comments. If no response is received from Duke and/or Licensee within [***] ([***])
[***] of the date the proposed publication/disclosure was received by Duke and Licensee, respectively, it will be conclusively presumed that the publication/disclosure may proceed without delay. If Duke and/or Licensee determines that the proposed
publication/presentation contains patentable subject matters which require protection, Duke and/or Licensee may require the delay of the publication/presentation for an additional period of time not to exceed [***] ([***]) [***] for the purpose of
allowing the pursuit of such protection. Patent applications shall be prepared, filed, prosecuted and maintained by the owner(s) of the subject patentable intellectual property unless an alternative arrangement is mutually agreed upon by all of the
owners of such patentable intellectual property and Licensee. 
 6. Any Material delivered pursuant to this Agreement is understood to be experimental in
nature, and NEITHER DUKE NOR LICENSEE MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE
MATERIAL AND/OR MODIFICATIONS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADE SECRET, TRADEMARK, OR OTHER RIGHTS. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, IT SHALL BE THE SOLE RESPONSIBILITY OF THE RECIPIENT INSTITUTION TO SECURE
RIGHTS UNDER ANY THIRD PARTY INTELLECTUAL PROPERTY RIGHTS THAT MAY BE REQUIRED FOR RECIPIENT INSTITUTION TO UTILIZE THE MATERIALS AND/OR MODIFICATIONS. 

  
 48 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
7. To the extent allowed by appertaining state or federal law and/or regulations, Recipient Institution agrees to defend, indemnify, and hold harmless Duke and Licensee from any loss, claim,
damage, or liability, of any kind whatsoever, which may arise from Recipient Institution’s use, storage or disposal of the Material and/or Modifications, and Recipient Institution assumes liability for damages which may arise from its use,
storage or disposal of the Material and/or Modifications. 
 8. In no event shall the Material or Modifications be used in human beings (including for
diagnostic purposes). Any research involving the Material and/or Modifications shall be conducted in accordance with all federal, state, local and other laws, regulations, and ordinances governing such research including applicable NIH guidelines.

 9. Notices or other correspondence required by this Agreement shall be sent via national/international courier service to both Duke and Licensee at the
following addresses, respectively: 
  

			
	 As to Duke:
	 	As to Licensee:
	 Office of Science and Technology

M454 Davison Building
 Box
3664, DUMC
 Duke University

Durham, NC 27710 USA

Attn.:
	 	 Cellective Therapeutics, Inc.
 4819 Emperor
Boulevard
 Suite 400
 Durham, NC 27703 USA

Attn.: President

 10. (a) This Agreement will terminate on the earliest of the following dates: (1) when the Material becomes generally
available, or (2) on completion of Recipient Institution’s proposed research studies with the Material, or (3) on [***] ([***]) [***] written notice by either Recipient Institution or Duke to the other, or (4) [***] ([***]) [***] from
the date that this Agreement is signed by Duke. 
 (b) On termination of this Agreement, Recipient Institution will discontinue its use of
the Material and will, upon direction of Duke, return or destroy the Material. Recipient Institution will also either destroy Modifications or remain bound by the terms of this Agreement as they apply to Modifications. 

(c) Paragraphs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10(b), 10(c), 10, 11, 12, and 13 shall survive any termination or expiration of this Agreement. 

11. This Agreement is not assignable by Recipient Institution without the proper written consent of both Duke and Licensee. 

12. Should any provision of this Agreement be held unenforceable or in conflict with the law of any jurisdiction, the validity of the remaining provisions
shall not be affected. 

  
 49 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
13. This Agreement contains the entire understanding between the parties relating to the subject matter hereof. No modification or amendment of any provision of this Agreement shall be binding
unless in writing expressly stated to be an amendment or modification and signed by the respective, authorized representative of each party. 
  

					
	 AGREED:
 Duke Scientist:
	 		 	Recipient Institution’s Scientist:
			
	   
	 		 	   

	(signature)                                     
                                         
       (date)	 		 	(signature)                                    
                                         
        (date)
			
	Printed Name:
                                         
                                         
    	 		 	Printed Name:
                                         
                                         
    
		 		 	
	Duke Approval:	 		 	Recipient Institution Approval:
			
	   
	 		 	   

	(authorized signature)
                                         
                               (date)	 		 	(authorized
signature)                                        
                         (date)
			
	Printed Name:
                                         
                                         
    	 		 	Printed Name:                                  
                                         
            
			
	Title:                                    
                                         
                            	 		 	Title:                                    
                                         
                            
			
	Address:	 		 	Address:
			
	   
	 		 	   

	   
	 		 	   

	   
	 		 	   

	   
	 		 	   

			
	Fax: #:                                    
                                         
                      	 		 	Fax: #:                                   
                                         
                       
			
	E-mail address:                            
                                         
                        	 		 	E-mail address:                           
                                         
                         

  
 50 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 APPENDIX C 

COMPANY PERFORMANCE MILESTONE SCHEDULE 

(TO BE DETERMINED AS SET FORTH IN SECTION 4.02) 

  
 51 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 APPENDIX D 

ROYALTY REPORT FORM (SAMPLE) 
  

																													
	Duke File #	  

	 Product (catalog # & description)
	  	Country	 	  	FDA
@@	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 SubTOTAL x Product
	  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 SubTOTAL x Product
	  				  				  				  				  				  				  			
	 SubTOTAL Duke File #
	  				  				  				  				  				  				  			

  

																													
	Duke File #	  

	 Product (catalog # & description)
	  	Country	 	  	FDA
@@	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 SubTOTAL x Product
	  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 SubTOTAL x Product
	  				  				  				  				  				  				  			
	 SubTOTAL Duke File #
	  				  				  				  				  				  				  			

  

																													
	 Duke File #
	  

	 Product (catalog # & description)
	  	Country	 	  	FDA
@@	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 SubTOTAL x Product
	  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 SubTOTAL x Product
	  				  				  				  				  				  				  			
	 SubTOTAL Duke File #
	  				  				  				  				  				  				  			

  
 52 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 SUBLICENSE NET SALES 

																													
	 Duke File #
	  

	 Product (catalog # & description)
	  	Country	 	  	FDA
@@	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 	  	Sales in
<Month>	 
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 SubTOTAL x Product
	  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 SubTOTAL x Product
	  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	 Duke File#
	  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
		  				  				  				  				  				  				  			
	GRAND TOTAL	  				  				  				  				  				  				  			

 ** Note that Reductions to Sales 

  
 53 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 APPENDIX E 

EXHIBIT B 
 MASTER DUKE TO
COMPANY MATERIAL TRANSFER AGREEMENT 
 (“MMTA”) 

between 
 Duke
University (“DUKE”) 
 Durham, NC 27705 

and 
 Cellective
Therapeutics, Inc. (“COMPANY”) 
 Pursuant to the terms of that certain License Agreement between Duke University and
Cellective Therapeutics, Inc. (effective date, ________________, 2004; hereinafter the “LICENSE AGREEMENT”), COMPANY may receive from [***] DUKE MATERIALS and KNOW-HOW of a tangible biological and/or
chemical nature (hereinafter, collectively, “ORIGINAL MATERIALS”). Unless defined in this MMTA, terms appearing in capital letters shall have the meaning ascribed such terms in the LICENSE AGREEMENT. 

For the purposes of this MMTA, “PROGENY” shall mean unmodified descendant(s) from the ORIGINAL MATERIALS, such as virus from virus,
cell from cell or organism from organism; “UNMODIFIED DERIVATIVES” shall mean substances created by COMPANY which constitute an important unmodified functional sub-unit or expression product of the
ORIGINAL MATERIALS which shall include, inter alia, subclones of unmodified cell lines, purified or fractionated sub-sets of the ORIGINAL MATERIALS such as novel plasmids or vectors, proteins expressed
by DNA or RNA, antibodies secreted by a hybridoma; “MATERIALS” shall mean ORIGINAL MATERIALS plus PROGENY plus UNMODIFIED DERIVATIVES; and “MODIFICATIONS” shall mean substances created by COMPANY which contain or incorporate any
form of the ORIGINAL MATERIALS, PROGENY or UNMODIFIED MATERIALS. ORIGINAL MATERIALS are provided under the following terms and conditions: 

1) Exchange of MATERIALS and MODIFICATIONS shall be documented through the use of Material Transfer Record Forms, a sample of which are
appended hereto as Exhibit I. Except as expressly stated in writing on the appertaining Material Transfer Record Form, all subject MATERIALS are and shall remain property of the DUKE. MATERIALS shall be used by COMPANY solely for the purposes
anticipated by the LICENSE AGREEMENT. COMPANY agrees to protect CONFIDENTIAL INFORMATION supplied by DUKE regarding MATERIALS in accordance with the confidentiality provisions set forth in the LICENSE AGREEMENT. 

  
 54 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 2) DUKE does not claim ownership of substances and MODIFICATIONS produced as a result of
COMPANY’s research with materials that are not included in the definition of MATERIALS above except as such substances and MODIFICATIONS are invented jointly by employees of DUKE and COMPANY (inventorship to be determined in accordance with
U.S. Patent Law). Notwithstanding the foregoing, DUKE retains ownership of any form of the MATERIALS contained in a MODIFICATION. 
 3)
Publication of the results of research using the MATERIALS or MODIFICATIONS shall be in accordance with the publication provisions set forth in the LICENSE AGREEMENT. COMPANY shall acknowledge DUKE as the source of the MATERIALS in any publication
of research results using the MATERIALS. 
 4) Transfer of MATERIALS conveys no rights to COMPANY under any patent applications, patents,
trade secrets or other proprietary rights of DUKE except as is conveyed under the LICENSE AGREEMENT. 
 5) Any MATERIALS delivered pursuant
to this MMTA are understood to be experimental in nature, and, in particular, the terms of Section 15.04 of the LICENSE AGREEMENT shall apply. 

6) In no event shall DUKE be liable for any use by COMPANY of MATERIALS or MODIFICATIONS and, in particular, the terms of Sections 15.01 and
15.02 of the LICENSE AGREEMENT shall apply. 
 7) All research involving the MATERIALS and/or MODIFICATIONS (including but not limited to
research involving the use of animals and recombinant DNA) shall be conducted in accordance with all federal, state, local and other laws, regulations or ordinances governing such research including applicable NIH guidelines. 

8) This MMTA will become effective on the effective date of the LICENSE AGREEMENT and shall terminate upon the termination or expiration of
the LICENSE AGREEMENT. On termination of the LICENSE AGREEMENT, COMPANY will immediately discontinue its use of MATERIALS and MODIFICATIONS thereof and will, upon direction of DUKE, return or destroy such MATERIALS and MODIFICATIONS as set forth for
DUKE MATERIALS in Section 10.09 of the LICENSE AGREEMENT. 
 9) Neither party may assign, delegate or otherwise transfer any of its
rights or obligations under this MMTA except as allowable in accordance with Article 14 of the LICENSE AGREEMENT. 
 10) Except as
specifically stated herein, this MMTA supersedes all previous or existing arrangements or agreements between the parties concerning transfer of MATERIALS and contains the entire understanding between the parties relating to the subject matter
hereof. No modification or amendment of any provision of this MMTA shall be binding unless in writing expressly stated to be an amendment or modification and signed by both parties. If there is any conflict between this MMTA and the LICENSE
AGREEMENT, the LICENSE AGREEMENT will govern. 

  
 55 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

									
	 AGREED:
	 		 	

									
			
	 DUKE UNIVERSITY
	 		 	      CELLECTIVE THERAPEUTICS, INC.

									
					
	By:	 	[***]	 		 	By:	 	 

									
	 [***]
	 		 		 		 	
	 Vice Chancellor
 Science and
Technology Development
	 		 		 	

									
					
	Date:	 	9/17/06	 		 	Date:	 	 

									
			
	 Principal Investigator
	 		 	  Principal Investigator

									
					
	By:	 	/s/ [***]	 		 	By:	 	 

									
		 		 		 		 	
					
	Date:	 	9/17/06	 		 	Date:	 	 

  
 56 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 EXHIBIT I 

MATERIAL TRANSFER RECORD 

Duke University (“DUKE”) 

Durham, NC 27705 
 to

 Cellective Therapeutics, Inc. (“COMPANY”) 

The Original Material(s) described below is (are) supplied by the DUKE to COMPANY subject to the terms and conditions of that certain License Agreement
between Duke University and Cellective Therapeutics, Inc. (effective date, ________________, 2004; hereinafter “LICENSE AGREEMENT”) and the MASTER DUKE TO COMPANY MATERIALS TRANSFER AGREEMENT to which this form is appended as Exhibit I.
Duplicate originals of this form shall be fully executed by the appropriate and authorized representatives of DUKE and COMPANY and one fully executed original provided to each party prior to transfer of the ORIGINAL MATERIALS (as such term is
defined in the MASTER DUKE TO COMPANY MATERIALS TRANSFER AGREEMENT). 
  

			
	Description of ORIGINAL MATERIALS and amount provided:	 	 
	
	 
	
	 
	
	 

  

									
	DUKE UNIVERSITY	 		 	      CELLECTIVE THERAPEUTICS, INC.

									
					
	By:	 	 	 		 	By:	 	 

									
	([***])	 		 		 	([***])	 	

									
					
	Name:	 	 	 		 	Name:	 	 

									
					
	Title:	 	 	 		 	Title:	 	 

									
					
	Date:	 	 	 		 	Date:	 	 

									
				
	Acknowledged	 		 		 	

									
					
	By:	 	/s/ [***]	 		 		 	

									
	[***]	 	Date  	 		 		 	

  
 57 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 

 
 CONFIDENTIAL 

September 9, 2005 
 [***] 

Vice Chancellor, Corporate and Venture Development 
 Duke
University 
 Box 3701, DUMC 
 Durham, NC 27710 

Dear [***]: 
 This letter will serve to amend
the License Agreement between Cellective Therapeutics, Inc. (“Cellective”) and Duke University (“Duke”), dated as of September 21, 2004 (the “Agreement”) and to
clarify the intent of the parties regarding certain provisions set forth in the Agreement. 
 1. Amendment to Recitals. Cellective and Duke
hereby agree to amend the recitals by replacing the first recital in its entirety as follows: 
 WHEREAS DUKE owns certain DUKE PATENT
RIGHTS (as hereinafter defined) relating to the following inventions submitted to the DUKE Office of Science and Technology (collectively, the “INVENTIONS”, and individually, “INVENTION”): 

 

	 	•	 	 [***]; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; and 

2. Amendment to Subsection 3.01(a). Cellective and Duke hereby agree to amend Subsection 3.01(a) of the Agreement by replacing the last sentence
thereof with the following language: 
 The right of DUKE to appoint an OBSERVER pursuant to this Subsection shall terminate upon the first
to occur of either (i) any CHANGE OF CONTROL of the COMPANY or (ii) the effectiveness of a registration statement for the sale of the COMPANY’s shares of Common Stock in a firm commitment underwritten public

  
 58 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
offering registered under the 1933 Act. As used herein, “CHANGE OF CONTROL” means any of the following events: (i) acquisition by a THIRD PARTY, whether by stock acquisition,
merger or otherwise, of the ownership of more than fifty percent (50%) of the voting securities or other ownership interest of the COMPANY, or (ii) acquisition by a THIRD PARTY, whether by stock acquisition, merger or otherwise, of all or
substantially all of the assets of the COMPANY to which this AGREEMENT relates. 
 3. Amendment to Section 4.01. Cellective
and Duke hereby agree to amend and restate Section 4.01 of the Agreement in its entirety as follows: 
  

	 	4.01	 COMPANY shall deliver to DUKE a draft of COMPANY’s business plan on or before September 15, 2005 and
a final version of COMPANY’s business plan within [***] ([***]) [***] after delivery of the draft business plan (hereinafter, the “FINAL COMPANY BUSINESS PLAN”). 

4. Limited Release and Acknowledgement. Duke hereby waives and forever discharges Cellective, its assigns, and successors, and any directors and
officers of the foregoing (each, a “Released Entity”), from any claims that Duke may have against any Released Entity arising out of, or relating to Cellective’s failure to provide a draft or final business plan pursuant
to the original Agreement. Duke acknowledges and agrees that, as of the date that Duke has executed this letter agreement, that (a) the Agreement is in full force and effect and has not been modified, changed, altered or amended in any respect
except as provided in this letter agreement and (b) to Duke’s best knowledge, Cellective is not in default in the performance or observance of any of its obligations under the Agreement, and there exists no event or condition which, with
notice or the lapse of time or both, would constitute such a default. 
 5. Amendment to Section 10.08. Cellective and Duke
hereby agree to amend and restate Section 10.08 of the Agreement in its entirety as follows: 
  

	 	10.08	 On or before the effective date of any termination of this AGREEMENT (but not any expiration pursuant to
Section 10.01), COMPANY shall cease the manufacture, use, practice, lease, and sale, offering, distribution and other commercialization of LICENSED PRODUCTS, LICENSED PROCESSES, and LICENSED SERVICES. For avoidance of doubt, any SUBLICENSE in
existence as of the effective date of any termination shall be unaffected by such termination other than the assignment and assumption provided for in Section 10.07. 

Notwithstanding the foregoing and for the avoidance of doubt, upon any expiration of this AGREEMENT pursuant to Section 10.01, COMPANY
shall not be restricted with respect to the manufacture, use, practice, lease, or sale, offering, distribution or other commercialization of LICENSED PRODUCTS, LICENSED PROCESSES, or LICENSED SERVICES. 

  
 59 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 6. Amendment to Section 10.09. Cellective and Duke hereby agree to amend
and restate Section 10.09 of the Agreement in its entirety as follows: 
  

	 	10.09	 Within [***] ([***]) [***] of any termination of this AGREEMENT (but not any expiration pursuant to
Section 10.01), COMPANY shall (i) return to DUKE or destroy, as directed by DUKE, all information, data, and any relevant materials provided to COMPANY during the term of this AGREEMENT (including, but not limited to, DUKE MATERIAL and KNOW-HOW), other than any of the foregoing items in the possession of a SUBLICENSEE, and (ii) destroy all LICENSED PRODUCTS (other than LICENSED PRODUCTS in the possession of any SUBLICENSEE or customer) in a
safe and legal manner. Further, COMPANY within such thirty (30) day period shall provide DUKE with a written statement signed by an authorized representative of COMPANY certifying the destruction of all LICENSED PRODUCTS (other than LICENSED
PRODUCTS in the possession of any SUBLICENSEE or customer) in a safe and legal manner, as well as the destruction of all said information, data, and relevant materials (including, but not limited to, DUKE MATERIAL and all KNOW-HOW), other than any of the foregoing items in the possession of a SUBLICENSEE, if such instructions for destruction are given by DUKE. 

Notwithstanding any of the limitations in Section 2.02 to the contrary, upon any expiration of this AGREEMENT pursuant to
Section 10.01, the KNOW-HOW LICENSE granted to COMPANY pursuant to Section 2.02 will automatically be converted to a non-exclusive, irrevocable, perpetual,
worldwide, fully-paid license, with the right to sublicense through multiple tiers of sublicenses. This paragraph of Section 10.09 (and the definitions necessary to give effect to this paragraph) shall survive expiration of this AGREEMENT to
the extent it is applicable. 
 7. Amendment to Appendix A. Cellective and Duke hereby agree to amend Appendix A of the Agreement by replacing item 2
thereof with the following language: 
  

	 	2.	 [***]; 

8. Amendment to Appendix A. Cellective and Duke hereby agree to amend Appendix A of the Agreement by replacing item 4 thereof with the following
language: 
  

	 	4.	 [***]. 

9. Additional Consideration. In consideration for the execution of this amendment to the Agreement, including but not limited to the amendment
to item 4 of Appendix A, Cellective shall make a one-time payment in the amount of [***] ($[***]) to Duke, such payment to be made within [***] ([***]) [***] of the execution of this amendment and in
accordance with the terms and conditions of the Agreement. 
 - remainder of page intentionally left blank - 

  
 60 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 The amendments set forth in this letter shall be effective upon signature hereof by both parties. Other than
as set forth in this letter, all of the terms and conditions of the Agreement shall continue in full force and effect. Please sign below and return to Cellective an executed copy of this letter to indicate your acceptance of the terms contained
herein. 
  

			
	Sincerely,
	
	/s/ [***]
	[***]	 	
	[***]	 	
	 Cellective Therapeutics, Inc.
	 	

  

			
	 Duke University

	
	 Agreed and Accepted

		
	By:	 	[***]
		
	Name:	 	[***]
		
	Title:	 	[***]

  
 61 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.EX-10.9

 Exhibit 10.9 

EXCLUSIVE LICENSE AGREEMENT 
 This
Agreement, effective as of September 21, 2004 (“Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 44
Binney Street, Boston, Massachusetts, 02115 (“DFCI”), and Cellective Therapeutics, Inc, a Delaware corporation having a principal place of business at 100 Capitola Drive, Suite 103, Durham, North Carolina 27713 (“Licensee”). 

Background 
 DFCI is the owner of certain rights in
technology as later defined, subject only to a royalty-free, nonexclusive license previously granted to the United States Government; and 
 DFCI desires to
have the rights used to promote the public interest by granting a license; 
 Licensee has represented to DFCI that it has the capabilities and/or
experience to develop and use the technology that is the subject of this Agreement to develop, produce, market and sell resultant products and has the financial capacity and the strategic commitment to facilitate the transfer of the technology for
the public interest; and 
 Licensee desires to obtain a license to DFCI’s rights and DFCI is willing to grant a license upon the terms and conditions
of this Agreement. 
 DFCI and Licensee therefore agree as follows. 

Article 1 — Definitions 
  

	1.1	 “Agreement” means this Exclusive License Agreement, including all attached schedules, which
are incorporated herein by reference. 

  

	1.2	 “Affiliate” means any company, corporation or other business entity that is controlled by,
controlling, or under common control with Licensee. For this purpose “control” means direct or indirect beneficial ownership of at least fifty percent (50%) interest in the voting stock (or the equivalent) of the company, corporation or
other business or having the right to direct, appoint or remove a majority of members of its board of directors (or their equivalents) or having the power to control the general management of the company, corporation or other business, by law or
contract. 

  

	1.3	 “Biological Materials” are those listed in Schedule 1, and any components, (such as nucleic
acids or proteins), subunits, progeny, or derivatives thereof, including, without limitation, humanized, recombinant, single chain, conjugated or other derivative forms of the antibodies produced by the hybridomas listed on Schedule 1.

  

	1.4	 “Field of Use” means all fields except research reagents. 

 

	1.5	 “First Commercial Sale” means the initial transfer of a Licensed Product or first delivery of
a Licensed Service, as the case may be, by or on behalf of Licensee, an Affiliate or Sublicensee for cash or non-cash consideration to which a fair market value can be assigned for purposes of determining Net
Sales. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	1.6	 “Licensed Intellectual Property” means, collectively, the Patent Rights and the Biological
Materials. 

  

	1.7	 “Licensed Process” means any process covered in whole or in part by an issued, unexpired claim
or a pending claim in Patent Rights or which incorporates or uses Biological Materials in whole or in part. 

  

	1.8	 “Licensed Product” means any product covered in whole or in part by an issued, unexpired claim
or a pending claim in the Patent Rights or products manufactured according to a Licensed Process or products that incorporate or use Biological Materials in whole or in part. A Licensed Product shall not include any product for which Biological
Materials are used in connection with the research, development or testing of such product, but into which no Biological Materials are incorporated and the manufacture or sale of which would not, without the License granted herein, infringe the
Patent Rights. 

  

	1.9	 “Licensed Service” means a service provided according to a Licensed Process.

  

	1.10	 “Net Sales” means the gross income derived by an entity licensed under this Agreement from the
Sales of Licensed Products or Licensed Services to independent third party customers in bona-fide arms-length transactions less the following deductions, which may not exceed reasonable and customary amounts in the country in which the transaction
occurs: 

 (a) Transportation charges or allowances actually paid or granted; 

(b) Trade, quantity, cash or other discounts and brokers’ or agents’ commissions, if any, actually allowed and taken; 

(c) Credits or allowances made or given on account of rejects, returns or retroactive price reductions for any amount not collected that are
specifically identifiable to Licensed Products; and 
 (d) Any tax or governmental charge directly on sale or transportation, use or delivery
of products paid by a licensed entity and not recovered from the purchaser. 
 Net Sales includes the fair market value of any non-cash consideration from sale of Licensed Products or Licensed Services received by Licensee, its Affiliates or Sublicensees. 

Licensed Products and Licensed Services are considered “Sold” when billed, invoiced or payment is received, whichever occurs first.

  

	1.11	 “Patent Rights” means the issued United States patents listed in Schedule 1 and any reissues,
reexaminations or extensions of such patents and any foreign counterparts of such patents. 

  
 2 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Patent Rights existing on the Effective Date are listed on Schedule 1. As of the Effective
Date there are no pending United States conversions, continuations, divisions or substitutions of the patents listed in Schedule 1. 
  

	1.12	 “Sale” or “Sold” means any grant, sale, lease, assignment, transfer, conveyance or
other disposition of Licensed Products or Licensed Services for value by or on behalf of Licensee, any Affiliate(s) or Sublicensee(s). 

  

	1.13	 “Sublicensee” means any natural person or legal entity, which is not an Affiliate, to which
Licensee grants a sublicense of some or all of the rights granted to Licensee under this Agreement. 

  

	1.14	 “Territory” means worldwide. 

Article 2 — Grant of Licenses, Options, Reserved Rights and Sublicensing 

 

	2.1	 (a) License Grants. Subject to all of the terms and conditions of this Agreement and the non-exclusive license granted to the United States government, DFCI grants to Licensee an exclusive, worldwide license to the Licensed Intellectual Property, with the right to grant sublicenses, to make, have made,
use, offer to sell, sell and import Licensed Products and Licensed Services and to practice Licensed Processes in the Territory for the Field of Use for the term of this Agreement. 

The license will continue for the term of this Agreement unless the grant is sooner terminated according to Article 8. 

 

	2.2	 Affiliates. Licensee is entitled to extend its licenses under this Article 2 to its Affiliates,
consistent with all of the terms and conditions of this Agreement. If Licensee does extend its license and an Affiliate assumes obligations under this Agreement, Licensee guarantees performance by the Affiliate. If DFCI has a claim arising under
this Agreement against an Affiliate, DFCI may seek a remedy directly against Licensee and may, but is not required to, seek a remedy against the Affiliate. Any termination of the Agreement under Article 8 as to Licensee also constitutes termination
as to any Affiliates. 

  

	2.3	 No Implied Licenses. This Agreement confers no license or rights by implication, estoppel or otherwise
under any other patent applications or patents owned in whole or in part by DFCI. 

  

	2.4	 Reserved Rights. The licenses granted by DFCI are subject to the following reserved rights.

  

	 	2.4.1	 The rights of the United States of America, as set forth in Public Laws
96-517 and 98-620, the regulations promulgated thereunder, and the policy of any funding agencies. Any rights granted hereunder, which are greater than permitted by
Public Laws 96-517 and 98-620, are subject to modification as required to conform to the provisions of those statutes. 

  
 3 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	2.4.2	 DFCI’s right to make and use the Licensed Intellectual Property in the Field of Use for its own use
and benefit for teaching, education and non-commercial research purposes, both laboratory and clinical. 

  

	 	2.4.3	 DFCI’s right to supply Biological Materials and to grant
non-exclusive, non-transferable licenses, without the right further to sublicense, to Patent Rights to other academic, governmental or not-for-profit organizations to make and use Licensed Intellectual Property for non-commercial research purposes in the Field of Use; provided, however, that such
licenses shall not be for use in human subjects, clinical trials or for diagnostic purposes involving human subjects. Upon request of Licensee, not more frequently than quarterly, DFCI shall provide Licensee a list of those academic, governmental or
not-for-profit organizations to whom it has granted licenses to Patent Rights and/or provided Biological Materials for permitted noncommercial research purposes in the
Field of Use. Notwithstanding the foregoing, Licensee acknowledges that DFCI has previously granted to Duke University, for Dr. Thomas Tedder, a sublicenseable right to practice under Patent Rights and to use Biological Materials for non-commercial research purposes as stated herein and to grant such rights (without the right to further sublicense) to others. Licensee agrees that it will seek to obtain any information it wishes with respect to
such transfers directly from Duke University. 

  

	2.5	 Sublicensing. Licensee has the right to grant sublicenses under this Agreement consistent with the terms
and conditions of this Agreement. Licensee shall be responsible for any Sublicensee’s compliance with the terms of this Agreement. 

  

	 	2.5.1	 Notice. Licensee shall promptly notify DFCI in writing of the identity of any prospective Sublicensee.

  

	 	2.5.2	 Form and Content of Sublicenses. Licensee shall issue any sublicense(s) granted by it under this
Agreement in writing and shall attach to each sublicense a copy of all provisions of this Agreement that are directly relevant to the Sublicensees’ rights and obligations under this Agreement. 

Licensee shall include the equivalent of at least the following provisions in all sublicenses. 

(a) Sublicensee shall use commercially reasonable efforts to bring the subject matter of the sublicense into commercial use as quickly as
possible and shall report annually to Licensee on its operations under the sublicense. 
 (b) Sublicensee shall make payments due to Licensee
in relation to Net Sales of Licensed Products and Licensed Services in a timely manner, so that Licensee may comply with its obligations to make payments to DFCI as set forth in Articles 3 and 4 of this Agreement. 

(c) The terms and conditions of Section 2.4, paragraphs 4.2.1 and 4.2.2, Sections 5.2 — 5.5, Section 6.1, 6.2, 7.1, 7.4 and 7.7,
Sections 8.4.4 and Articles 9, 10 and 12 of this Agreement are binding on the Sublicensee. In addition, Licensee shall make the Sublicensee aware of the provisions of Section 8.4.4. 

  
 4 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (d) Sublicensees do not have the right to grant further sublicenses. 

 

	 	2.5.3	 Copies of Sublicenses to DFCI. Licensee shall forward to DFCI a copy of any and all fully executed
sublicenses. Such copy shall be postmarked within [***] of the execution of the sublicense. Licensee shall also forward to DFCI annually a copy of the reports received by Licensee from its Sublicensee during the preceding [***] ([***]) [***] under
the sublicenses as shall be pertinent to (1) its operations under the sublicense and (2) a royalty accounting under the sublicense agreement. 

  

	 	2.5.4	 Licensee’s Continuing Obligations. Nothing in Section 2.5 may be construed to relieve Licensee
of its obligations to DFCI under this Agreement, including but not limited to Licensee’s obligations under Article 9. 

Article 3 — Consideration—Amounts and Time for Payment 

In consideration of the rights granted by DFCI to Licensee under this Agreement, Licensee shall make the following payments to DFCI according to this Article
3 and Article 4, which payments are in respect of use of the Licensed Intellectual Property by Licensee, any Affiliate(s) or Sublicensee(s), as specified below. 
  

	3.1	 Reimbursements and Other Financial Consideration 

 

	 	3.1.1	 Past Patent Expenses. Within [***] ([***]) [***] after the Effective Date, Licensee shall reimburse DFCI
for all documented unreimbursed out-of-pocket expenses incurred and paid by DFCI before the Effective Date for filing, prosecuting, maintaining and enforcing Patent
Rights. Licensee acknowledges that the total amount of these patent expenses is [***] ([***]). The parties acknowledge that Licensee has thus far reimbursed [***] ([***]) of these patent expenses in consideration of the grant on January 23,
2004, of an option to be granted the exclusive, worldwide license to the Licensed Intellectual Property and such sum will be fully credited toward Licensee’s obligation under this paragraph. 

 

	 	3.1.2	 Future Patent Expenses. Subject to the provisions of Section 6.3 below, Licensee shall pay all
further out-of-pocket patent expenses incurred or paid by DFCI on or after the Effective Date and prior to the transfer of patent prosecution to Licensee as provided in
Article 7, including any out-of-pocket costs incurred in connection with such transfer. Licensee shall pay DFCI within [***] ([***]) [***] after DFCI mails Licensee an
invoice that documents the out-of-pocket expenses incurred and paid by DFCI during the period being invoiced and states the total amount owed to DFCI. Upon and after
transfer of patent prosecution to Licensee, DFCI shall not incur, or undertake to incur, patent expenses in an amount greater than [***] without the prior written consent of Licensee, such consent not to be unreasonably withheld or delayed.

  
 5 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	3.1.3	 Initial License Fee. Upon execution of this Agreement, subject to the terms and conditions set forth
below, Licensee shall issue to DFCI [***] of Licensee’s common stock, $0.001 par value per share (“Common Stock”). It shall be a condition to DFCI’s right to acquire shares hereunder that Licensee may, in its discretion, require
that in the opinion of counsel for Licensee the proposed acquisition shall be exempt from registration under the Securities Act of 1933, as amended, and DFCI shall have made such undertakings and agreements with Licensee as Licensee may reasonably
require, and that such other steps, if any, as counsel for Licensee shall deem necessary to comply with any law, rule or regulation applicable to the issue of such shares by Licensee shall have been taken by Licensee or DFCI, or both. The
certificates representing the shares acquired hereunder may contain such legends with respect to the restrictions set forth above and as counsel for Licensee shall deem necessary to comply with the applicable law, rule or regulation.

  

	 	3.1.4	 Milestone Payments. With respect to Licensed Intellectual Property, Licensee shall make the following
milestone payments to DFCI within [***] ([***]) [***] of the occurrence of each of the following events, whether Licensee, an Affiliate or Sublicensee achieves the events. 

-Two Hundred Fifty Thousand Dollars ($250,000) upon each of the first three corporate alliances or other agreements entered into by Licensee
with a third party, where such agreement includes the Licensed Intellectual Property, whether practiced by Licensee or the other party(ies) in the alliance and from which agreement Licensee receives funds of any type (except for payment for equity
at a fair market value) of an aggregate of at least $2,000,000. The term “fair market value” shall mean: (a) if Licensee’s Common Stock is publicly traded, the value of such equity using a per share price equal to the average of
the reported closing prices of such stock on the exchange for the twenty (20) trading days prior to such purchase; or (b) otherwise, the value of such equity using the per share purchase price of Licensee’s most recent equity
financing. 
 At the time each milestone payment is due, Licensee may offer (in its discretion) to make the milestone payment in cash or with
the grant of additional equity to DFCI. If DFCI has sound reasons to decline equity as payment, Licensee will pay the full amount of the milestone payment in cash. Under such circumstances, Licensee will make the cash payments in [***] ([***]) [***]
payments commencing with the due date and at [***] intervals thereafter. 
  

	 	3.1.5	 Running Royalties. Licensee shall pay DFCI the following running royalties on Net Sales by Licensee, its
Affiliates or Sublicensees as follows: 

 (a) [***] ([***]) of Net Sales of Licensed Products or Licensed Services. 

(b) [***] ([***]) of Net Sales of Licensed Products or Licensed Services which incorporate or use only the Biological Materials and are not
covered by any unexpired claim in the Patent Rights. 

  
 6 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	3.1.6	 Sublicense Income. Licensee shall pay DFCI a royalty of [***] of Sublicense Income if only Licensed
Intellectual Property is included in the grant of rights to a third party. “Sublicense Income” includes sublicense royalties (other than any running royalties), license issue fees, license milestone payments, license maintenance fees,
technology access fees, and any similar payments made by Sublicensees to Licensee or an Affiliate on account of licenses that include the grant of sublicenses under this Agreement. Excluded from Sublicense Income are (a) running royalties,
(b) payments that are fees for services, (c) payments for equity, and (d) payments received in connection with any sublicenses for which milestone payments are made under Subsection 3.1.4, above. In the event Licensee grants rights to
a Sublicensee to both Licensed Intellectual Property and patent rights or other technologies owned or controlled by Licensee that are not included in the Licensed Intellectual Property and the purpose, use and function of which are related to the
purpose, use and function of the Licensed Intellectual Property (a “Joint Property License”), then Licensee shall pay DFCI a royalty of [***] ([***]) of Sublicense Income from the Joint Property License. All other licenses granted by
Licensee containing both Licensed Intellectual Property and unrelated patent rights or other technologies shall be subject to the royalty of [***] of the Sublicense Income for that portion of the income attributable by reasonable allocation to the
Licensed Intellectual Property. Licensee shall pay these royalties to DFCI within [***] ([***]) [***] of each calendar quarter in which the Sublicense Income is received by Licensee or its Affiliate. For avoidance of doubt, in the event Licensee
sublicenses any of the Licensed Intellectual Property to a Sublicense, the applicable running royalty amount set forth in Subsection 3.1.5 payable on such Sublicensee’s Net Sales of Licensed Products or Licensed Services shall be due to DFCI
from Licensee irrespective of the amount of running royalty due or payable to Licensee under such sublicense. 

  

	3.2	 Waiver or Deferral. Waiver or deferral by DFCI of any payment owed under any paragraph under
Section 3.1 may not be construed as a waiver or deferral of any subsequent payment owed by Licensee to DFCI. 

  

	3.3	 Combination Packages. If a Licensed Product or Licensed Service is sold in a combination package or kit
containing other active products or, processes or services, then Net Sales for purposes of determining royalty payments on the combination package will be calculated using one of the following methods, but the royalties payable to DFCI may not be
reduced to less than [***] ([***]) of that provided for in paragraph 3.1.5 of this Agreement: 

 By multiplying the Net
Sales of the combination by the fraction A/A+B, where A is the gross selling price, during the royalty-paying period in question, of the Licensed Product or Licensed Service sold separately, and B is the gross selling price during the royalty period
in question, of the other active products, processes or services sold separately; or 

  
 7 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 If no separate sales are made of the Licensed Product or Licensed Service or any of the
active products in such combination package during the royalty-paying period in question, Net Sales for the purposes of determining royalty payments, must be calculated by dividing the Net Sales price of the combination by the number of functions
performed by the combination sold where such combination contains active agents or processes other than those licensed under this Agreement. 
  

	3.4	 Reduced Rate after Expiration of Patents. Licensee’s obligation to pay running royalties to DFCI
under paragraphs 3.1.5(a) and 3.1.6 terminates on a country-by-country basis upon expiration of the
last-to-expire patent in the applicable country. However, in recognition of the ongoing value of the Biological Materials, Licensee shall continue to pay DFCI running
royalties on Net Sales of Licensed Products and Licensed Services at the rate set forth in paragraph 3.1.5 (b) for so long as Licensed Products and Licensed Services are sold in the various country(ies). 

Article 4 — Royalty Reports, Payments and Financial Records 

 

	4.1	 Royalty Reports. Within [***] ([***]) [***] after March 31, June 30, September 30 and
December 31, of each year in which this Agreement is in effect, Licensee shall deliver to DFCI full, true and accurate reports of its activities and those of its Affiliates or Sublicensee(s), if any, relating to this Agreement during the
preceding [***] period. These reports must include at least the following: 

 (a) Number of Licensed Products manufactured
and sold by Licensee, and any Affiliates or Sublicensees, in each country of the Territory; 
 (b) Total billings for the Licensed Products
and Licensed Services sold; 
 (c) Deductions applicable to determining Net Sales; 

(d) The nature and amount of Non-Running or Sublicense Income received by Licensee; 

(e) Total royalties due to DFCI; 

(f) After the date of First Commercial Sale in any country, a summary of the activities of Licensee, and any Affiliates and Sublicensees,
directed toward promoting the sale of Licensed Products and Licensed Services in the Territory. 
 With each report, Licensee shall pay to
DFCI the royalties due and payable. If no royalties are due, Licensee shall so report. If multiple Licensed Products and Licensed Services are covered by the license granted under this Agreement, Licensee shall separately identify each Licensed
Product or Licensed Service (as the case may be) in the royalty report and specify which patents/application within Patent Rights, Biological Materials are used for each Licensed Product or Licensed Service. 

In no event shall Licensee be required to pay multiple royalties to DFCI based on sales of the same Licensed Product or Licensed Service based
on such Licensed Product’s or Licensed Service’s being covered by multiple Patent Rights. 

  
 8 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	4.2	 Record Keeping. 

 

	 	4.2.1	 Books and Records. Licensee shall keep, and shall require its Affiliates and Sublicensees to keep, true
books of account containing an accurate record (together with supporting documentation) of all data necessary for determining the amounts payable to DFCI. Licensee shall keep its records at its principal place of business or the principal place of
business of the appropriate division of Licensee to which this Agreement relates and shall require its Affiliates and Sublicenses to keep their books and records in the same manner. 

 

	 	4.2.2	 Inspections. In order for DFCI to determine the correctness of any report or payment made under this
Agreement, Licensee shall make its records available to DFCI for inspection, for a period of three (3) years following the end of the calendar year to which they pertain. License shall also require any Affiliates or Sublicensees to make their
records available for inspection by DFCI, in the same manner as provided in this paragraph 4.2.2. 

 DFCI may inspect the
records at mutually acceptable times during regular business hours by a certified public accountant selected by DFCI and reasonably acceptable to the licensed entity whose records are being inspected. DFCI shall request access to such records in
writing at least [***] ([***]) [***] prior to the desired date of inspection. In conducting inspections under this paragraph 4.2.2, Licensee agrees that DFCI’s accountant may have access to all records which DFCI reasonably believes to be
relevant to calculating royalties owed to DFCI under Article 3. 
 DFCI is responsible for the cost of any inspection, unless the examination
shows an underreporting or underpayment by any entity in excess of five percent for any twelve month period, in which case Licensee shall pay the cost of the inspection as well as any additional sum that would have been payable to DFCI had the
Licensee reported correctly, plus interest as set forth in Section 4.5. 
  

	4.3	 Form of Payments and Taxes. Licensee must make all payments to be made to DFCI in Boston, Massachusetts,
or at such other place or in such other way as DFCI may reasonably designate. Payments must be paid by check or wire transfer. 

Licensee shall pay all amounts payable to DFCI under this Agreement in United States funds without deduction for taxes, exchange, collection or
other charges that may be imposed by any country or political subdivision with respect to any amounts payable to DFCI under this Agreement, except that Licensee shall collect such amounts to the extent required to do so by applicable law. To the
extent required to do so by applicable law, Licensee shall be responsible for paying, or ensuring payment of, such taxes, exchange, collection or other charges. 
  

	4.4	 Currency Conversion. If any currency conversion is required in connection with any payment owed to DFCI,
the conversion will be made at the buying rate for the transfer of such other currency as quoted by the Wall Street Journal on the last business day of the applicable accounting period in the case of any payment payable with respect to a specified
accounting period or, in the case of any other payment, the last business day before the date the payment is due. 

  
 9 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	4.5	 Interest. Any payment owed to DFCI under this Agreement that is not made when due will accrue interest
beginning on the first day following the due date specified in Article 3. The interest will be calculated at the annual rate of the sum of (a) [***] ([***]) plus (b), the prime interest rate quoted by Bank of America on the date the payment is due,
the interest being compounded on the last day of each calendar quarter. However, the annual rate may not exceed the maximum legal interest rate in Massachusetts. The payment of interest as required by this Section does not foreclose DFCI from
exercising any other rights or remedies it has as a consequence of the lateness of any payment. 

 Article 5 —
Operations under the License 
  

	5.1	 Due Diligence 

 

	 	5.1.1	 General Obligations. Licensee shall use reasonable commercial efforts to bring one or more Licensed
Products or Licensed Services to the marketplace as soon as reasonably practicable, through a diligent and aggressive program of development, production and distribution. Such efforts must not be less than the efforts expended by Licensee in
connection with its other high priority projects. After commercialization, Licensee shall use reasonable commercial efforts to keep Licensed Products or Licensed Services available to the public. 

 

	 	5.1.2	 Development Plan. Within [***] ([***]) [***] after the Effective Date, Licensee shall provide DFCI with
a bona fide written development plan that describes Licensee’s plan for bringing the subject matter of the Licensed Intellectual Property to practical application (the “Development Plan”). The Development Plan must set forth the
particular Licensed Products or Licensed Services and practical applications of Licensed Products or Licensed Services that Licensee initially intends to develop, cite Licensee’s specific goals and objectives for the ensuing year for developing
or commercializing the Licensed Intellectual Property and outline Licensee’s plan for achieving the specific due diligence obligations set forth in Section 5.1.3 below. The outline must include actual or projected financial resources or
strategic alliances that will be required to meet such objectives. 

  

	 	5.1.3	 Specific Diligence Benchmarks. Licensee shall use commercially reasonable efforts to meet the following
specific effort and achievement benchmarks (“Diligence Benchmarks”) by the dates specified in this paragraph. 

(a) For the first [***] ([***]) of the term of this Agreement, Licensee’s annual expenditure on research and product development
pertaining to the Licensed Intellectual Property of an amount equal to [***] ([***]) of Licensee’s operations budget (including salaries and overhead) on research and product development pertaining to the Licensed Intellectual Property. Such
expenditure may be made by Licensee, or by others beneficially for Licensee. 

  
 10 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 (b) [***]. 

(c) [***]. 
 (d) [***]. 

[***]. 
  

	 	5.1.4	 Adjustments. The Diligence Benchmarks or dates set forth above may be adjusted by mutual agreement by
the parties, which agreement will not be unreasonably withheld by DFCI if Licensee can demonstrate that good faith efforts were made to achieve the Diligence Benchmarks and that the failure to achieve Diligence Benchmarks were due to scientific,
technical or regulatory reasons beyond the reasonable control of Licensee. 

  

	 	5.1.5	 Development and Commercialization Reports. Licensee shall provide to DFCI a written report, due on each
anniversary of the Effective Date, describing the efforts by Licensee, or any Affiliates or Sublicensees, to bring one or more Licensed Products or Licensed Services to the marketplace during the preceding year. The report must be in sufficient
detail to permit DFCI to monitor Licensee’s compliance with the due diligence provisions of this Agreement. 

Licensee shall include at least the following in these reports: (a) a summary of Licensee’s progress toward meeting the goals and
objectives that had been established for the previous year; (b) a summary of Licensees goals and objectives for the ensuing year for developing and commercializing Licensed Intellectual Property including an identification of additional
Licensed Products or Licensed Services that Licensee intends to develop, if any; and (c) to the extent not covered by the foregoing, a summary of Licensee’s progress in meeting the Diligence Benchmarks of Section 5.1.3. 

If multiple technologies are covered by this Agreement, the progress report must provide the information set forth above for each Licensed
Product or Licensed Service. 
  

	 	5.1.6	 Failure to Perform. Licensee’s failure to perform with any due diligence requirement provided in
any paragraph in this Section 5.1, subject only to adjustments pursuant to Section 5.1.4, is grounds for DFCI to terminate this Agreement according to Section 8.2.3. 

 

	5.2	 U.S. Manufacture. Licensee shall manufacture Licensed Products leased, used or sold in the United States
substantially in the United States as required by 35 U.S.C. 204 and 37 C.F.R. 401 et. seq., as amended. Licensee shall also require any Affiliate(s) or Sublicensee(s) to comply with this U.S. manufacture requirement. 

 

	5.3	 Other Government Laws. Licensee shall comply with, and shall require its Affiliates and Sublicensees to
comply with, all government statutes and regulations that relate to Licensed Products. These include but are not limited to FDA statutes and regulations, the Export Administration Act of 1979, as amended, codified in 50 App. U.S.C. 2041 et seq. and
the regulations promulgated thereunder or other applicable export statutes or regulations. 

  
 11 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	5.4	 Patent Marking. Licensee shall mark, and shall require its Sublicensees and Affiliates to mark, all
Licensed Products sold in the United States with the word “Patent” and the number or numbers of issued patents comprising the Patent Rights applicable to the Licensed Product. 

 

	5.5	 Publicity — Use of Name. Licensee, its Affiliates and Sublicensees are not permitted to use the
names of DFCI, its related entities or its employees, or any adaptations thereof, in any advertising, promotional or sales literature, or in any securities report required by the Securities and Exchange Commission, without the prior written consent
of DFCI in each case provided, however, that Licensee may (a) refer to publications in the scientific literature by employees of DFCI, (b) state that a license from DFCI has been granted as provided in this Agreement, (c) refer to
DFCI as a shareholder or licensor of Licensee to the extent required by applicable law, or (d) state that Dr. Thomas Tedder is a former employee of DFCI. 

Article 6 — Patent Preparation, Filing, Prosecution and Maintenance 

 

	6.1	 Responsibility. Subject to the provisions of Section 6.3 below, Licensee is responsible for
preparing, filing, prosecuting and maintaining the patent applications and patents included within the Patent Rights and for paying all associated costs. For purposes of this Agreement, patent prosecution includes ex parte prosecution, interference
proceedings, reissues, reexaminations and oppositions. Licensee shall provide, or cause its agent to provide, copies of relevant correspondence between Licensee and the United States Patent Office or the various foreign patent offices and give DFCI
reasonable opportunity to advise Licensee or Licensee’s counsel on such matters. DFCI designates the following individual or department for receiving the patent-related correspondence. 

Patent Counsel 
 Office of Patent
Counsel 
 Dana-Farber Cancer Institute 

44 Binney Street 
 Boston, MA
02115 
 Upon DFCI’s request, Licensee shall be available to consult with DFCI on matters relating to preparing, filing, prosecuting or
maintaining any of the applications or patents within the Patent Rights. Licensee shall consider the reasonable, legitimate interests of DFCI as owner of the Patent Rights in performing its responsibility under this Section 6.1. Licensee
designates the following individual or department to receive such requests from DFCI. 
 [***] 

[***] 
 Cellective Therapeutics

 100 Capitola Drive, Suite 103 

Durham, NC 27713 

  
 12 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	6.2	 Cooperation. DFCI shall cooperate with Licensee in preparing, filing, prosecuting and maintaining the
patent applications and patents within Patent Rights. The parties shall provide prompt notice to each other of any matter that comes to their attention that may affect the patentability, validity or enforceability of any patent application or patent
within Patent Rights. 

  

	6.3	 Relinquishing Rights. If Licensee elects not to prepare, prosecute and/or maintain any patents or patent
applications in any country(ies) or region(s) in the world, Licensee shall give DFCI written notice of such election at least [***] ([***]) [***] prior to any applicable due date or bar date; relinquish responsibility for prosecution of said non-elected application or patent; and surrender its license under such non-elected patent or patent application. However, if Licensee is surrendering any patent or
application within Patent Rights on which an interference proceeding or opposition has been declared or filed, the notice period is [***] ([***]) [***]. If Licensee so surrenders its rights, it will remain responsible for any patent annuities
required to be paid and all reasonable patent-related expenses required to be paid to preserve the pendency of the patent applications included in the Patent Rights during the applicable notice period. Thereafter, Licensee will have no further
obligation to pay any patent expenses for the patents or patent applications that it surrendered. Licensee’s election to relinquish its license with respect to any Patent Rights in any country or countries shall have no effect on its license
with respect to such Patent Rights in any other country or countries or any other Patent Rights licensed hereunder. 

  

	6.4	 Prosecution by DFCI. Upon Licensee’s relinquishing responsibility for prosecution and surrendering
its license pursuant to Section 6.3, DFCI shall thereafter have the right, but not any obligation, to prosecute, obtain issuance of, and/or maintain such Patent Rights relinquished by Licensee in such country(ies) or region(s) at its own cost,
and any such applications and resultant patents shall not be subject to this Agreement. 

 Article 7 — Patent
Infringement and Enforcement 
  

	7.1	 Notice. If at any time during the term of this Agreement, either Licensee or DFCI becomes aware of an
apparent infringement in a particular country of a patent within Patent Rights, it will promptly notify the other party of such alleged infringement, regardless of whether it chooses to take action against the alleged infringer.

  

	7.2	 Action by Licensee 

 

	 	7.2.1	 Procedure. Licensee shall have the first right, but not the obligation, for enforcing the Patent Rights
and prosecuting apparent infringers at its expense and in its own name when, in its judgment, such action may be reasonably necessary and justified. Before Licensee commences any legal proceeding with respect to the infringement, Licensee shall
consider in good faith the views of DFCI. Licensee’s election not to pursue any apparent infringer shall have no effect on the rights granted to Licensee under this Agreement. 

If Licensee notifies DFCI that it intends to prosecute the alleged infringer, then Licensee has [***] ([***]) [***] from the date of its notice
to DFCI to either (a) cause the infringement to terminate or (b) initiate legal proceedings against the alleged infringer. If any such suit is brought by Licensee in its own name it will be at Licensee’s expense and on its own behalf.
Licensee has the right to join DFCI as a party-plaintiff if required by law, at Licensee’s expense. 

  
 13 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	7.2.2	 Action at Request of DFCI. DFCI may request Licensee to take reasonable steps to protect the Patent
Rights from an apparent infringement. Licensee shall notify DFCI, within [***] ([***]) [***] of receiving a written request from DFCI, of action Licensee intends to take, if any, to compel termination of the alleged infringing action or to initiate
legal proceedings against the alleged infringer. 

  

	 	7.2.3	 DFCI Right to Join. DFCI has the right to join any legal proceeding brought by Licensee under this
Section 7.2 using DFCI’s own counsel and at DFCI’s own expense. If DFCI elects to join as a party plaintiff pursuant to this paragraph 7.2.3, DFCI may jointly participate in the action with Licensee, but Licensee’s counsel will
be lead counsel. 

  

	 	7.2.4	 Settlement. In any legal proceeding initiated by Licensee, no settlement, consent judgment or other
voluntary final disposition of the legal proceeding that adversely affects DFCI may be entered into without the consent of DFCI, which consent shall not be unreasonably withheld or delayed. 

 

	7.3	 Action by DFCI 

 

	 	7.3.1	 Procedure. If Licensee notifies DFCI that it does not intend to prosecute an infringement, or if
Licensee fails to cause the infringement to terminate or initiate legal proceeding to compel termination within [***] ([***]) [***] of the date of its notice to DFCI pursuant to paragraph 7.2.1, above, then DFCI may initiate legal proceedings
against the alleged infringer, at DFCI’s expense and on its own behalf according to the terms of this Section 7.3. Before DFCI commences any legal proceeding with respect to the infringement, DFCI shall consider in good faith the views of
Licensee. DFCI has the right to join Licensee as a party plaintiff if required by law, at DFCI’s expense. 

  

	 	7.3.2	 Licensee’s Right to Join. Licensee has the right to join any legal proceeding brought by DFCI under
this Section 7.3 using Licensee’s own counsel and at Licensee’s own expense. If Licensee elects to join as a party plaintiff pursuant to this paragraph 7.3, Licensee may jointly participate in the action with DFCI, but DFCI’s
counsel will be lead counsel. 

  

	 	7.3.3	 Settlement. Regardless of whether Licensee is joined or joins any legal proceeding initiated by DFCI, no
settlement, consent judgment or other voluntary final disposition of the legal proceeding may be entered into without the consent of DFCI, which consent shall not be unreasonably withheld or delayed. 

 

	7.4	 Cooperation. If one party initiates legal proceedings to enforce the Patent Rights pursuant to this
Article 7, the other party shall cooperate with and supply all assistance reasonably requested by the party initiating the proceedings, at the initiating party’s request and expense. 

  
 14 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	7.5	 Distribution of Amounts Paid by Third Parties. In any legal proceeding brought by Licensee, DFCI or
jointly by Licensee and DFCI pursuant to this Article 7, any recovery or proceeds of such proceeding, whether characterized as damages, costs, attorneys’ fee awards or otherwise, shall be distributed as follows: (a) each party shall first
be reimbursed pro rata for its reasonable attorneys’ fees and out-of-pockets expenses actually incurred in connection with the proceeding; (b) DFCI shall
second recover a sum equivalent to the total amount of royalties and sublicense or partnering income royalties deducted by Licensee under Section 7.6, if any; (c) Licensee shall third recover an amount equal to its lost profits or a
reasonable royalty (whichever measure of damages has been applied in the legal proceeding or settlement thereof); (d) DFCI shall then receive the amount for royalties that Licensee would have owed to DFCI under this Agreement if Licensee had made
the infringer’s sales directly, to the extent such award compensates Licensee for such sales, the amount of such royalties not to exceed the amount of any lost profits or reasonable royalty award (whichever measure of damages has been applied
in the legal proceeding or settlement thereof); and (e) the balance, if any, will be divided on a pro rata basis between the parties according to their respective percentage contributions to the total documented cost and expense of the
proceeding, including each party’s reasonable attorney’s fees. 

  

	7.6	 Reduction of Royalties. If Licensee initiates legal proceedings under Section 7.2 in any country
and DFCI does not voluntarily join the proceeding, License may deduct up to [***] ([***]) of Licensee’s documented costs and expenses of the proceeding (including reasonable attorney fees) from running royalties payable to DFCI under paragraph
3.1.5 of this Agreement from sales of Licensed Products or Licensed Services covered by the patent(s)-in-suit. However, Licensee may not reduce DFCI’s royalty
payments by more than [***] ([***]) of the amount otherwise due under Article 3. If Licensee’s costs and expenses exceed [***] ([***]) of the amount of royalties deducted by Licensee for any calendar year, Licensee may, to that extent, reduce
the royalties due to DFCI in succeeding calendar quarters for so long as Licensee is actively engaged in legal proceedings to terminate the infringement. However, Licensee may not reduce total royalties due to DFCI in a given calendar quarter by
more than [***] ([***]). Licensee’s right to reduce royalty payments to DFCI under this paragraph 7.6 applies only for so long as the legal proceeding continues. 

 

	7.7	 Declaratory Judgment Actions. In the event that any third party initiates a declaratory judgment action
or counterclaim alleging the invalidity or unenforceability of the Patent Rights, or if any third party brings an infringement action against Licensee or its Affiliates or Sublicensees because of the exercise of the rights granted Licensee under
this Agreement, then in either such event Licensee shall have the right to defend such action under its own control and at its own expense; provided, however, that DFCI shall have the right to intervene and jointly participate in the defense of such
claims or counterclaims (as the case may be), at its own expense. Neither party shall enter into any settlement, consent judgment or other voluntary final disposition of any action under this Section 7.7 without the prior written consent of the
other party, which consent shall not be unreasonably withheld or delayed unless the settlement includes any express or implied admission of liability or wrongdoing on DFCI’s or Licensee’s part, in which case DFCI’s or Licensee’s
respective right to grant or deny consent is absolute and at its sole discretion. Any recovery shall be distributed as described in Section 7.5. 

  
 15 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Article 8 — Term and Termination 

 

	8.1	 Term. Unless terminated earlier under the provisions of this Agreement, this Agreement will terminate on
the expiration date of the last to expire of patents within Patent Rights except that if a Licensed Product incorporates or uses a Biological Material in whole or in part, or such product is manufactured by a Licensed Process which incorporates or
uses a Biological Material, in whole or in part; or a, Licensed Service is provided according to a Licensed Process which incorporates or uses a Biological Material, in whole or in part or a process for the manufacture of a product uses Biological
Material, this Agreement will terminate when Licensee ceases to sell any such Licensed Products or Licensed Services or ceases to manufacture products using any such Licensed Process. 

 

	8.2	 Termination by Licensor. DFCI has the right to immediately terminate this Agreement and all licenses
granted hereunder by providing Licensee with written notice of termination, upon the occurrence of any of the following events: 

  

	 	8.2.1	 Licensee ceases to carry on its business with respect to Licensed Products or Licensed Services.

  

	 	8.2.2	 Licensee fails to pay on schedule any royalty or other payment that has become due and is payable under
Articles 3 or 4 of this Agreement and has not cured the default by making the required payment, together with interest due, within thirty (30) days of receiving a written notice of default from DFCI requesting such payment.

  

	 	8.2.3	 Licensee fails to comply with any due diligence obligation provided for in Section 5.1, unless
Licensee has cured the default by meeting the obligation within sixty ninety (90) days of receiving written notice of default from DFCI. 

  

	 	8.2.4	 Licensee defaults in its obligations to procure and maintain insurance under Section 9.2.

  

	 	8.2.5	 Licensee is convicted of a felony relating to the manufacture, use, sale or importation of Licensed
Products or Licensed Services. 

  

	 	8.2.6	 Licensee materially breaches any other provision of this Agreement, unless Licensee has cured the breach
within ninety (90) days of receiving written notice from DFCI specifying the nature of the breach. 

  

	8.3	 Termination by Licensee. Licensee has the right to terminate this Agreement without cause by giving DFCI
one hundred and eighty (180) days prior written notice. 

  

	8.4	 Effect of Termination. 

 

	 	8.4.1	 No release. Upon termination of this Agreement for any reason, nothing in this Agreement may be
construed to release either party from any obligation that matured prior to the effective date of the termination. 

  
 16 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	8.4.2	 Survival. The provisions of Article 4 (Royalty Reports, Payments and Financial Records),
Section 5.5 (Publicity — Use of Names), paragraph 8.4.2 (Survival), 8.4.3 (Inventory), 8.4.4 (Sublicenses), Sections 9.1 — 9.5 (Indemnification and Defense), Sections 9.6 — 9.9 (Insurance) and Articles 10-21 shall survive termination of this Agreement. 

  

	 	8.4.3	 Inventory. Licensee, any Affiliate(s) and any Sublicensees whose sublicenses are not converted as
provided in paragraph 8.4.4, may, after the effective date of termination, sell all Licensed Products and Licensed Services that are in inventory as of the date of written notice of termination, and complete and sell Licensed Products which the
licensed entity(ies) can clearly demonstrate were in the process of manufacture or performance, as the case may be, as of the date of written notice of termination, provided that Licensee shall pay to DFCI the royalties thereon as required by
Article 3 and shall submit the reports required by Article 4 on the sales of Licensed Products and Licensed Services. 

  

	 	8.4.4	 Sublicenses. Any sublicenses will terminate contemporaneously with this Agreement;
provided, however, any Sublicensee not in default under its sublicense may convert such sublicense to a license directly between DFCI and Sublicensee upon written notice to DFCI, provided further that such Sublicensee
agrees in writing to be bound by the following provisions of this Agreement: Sections 2.4, 2.5, 3.1.1, 3.1.2, 4.2.1, 4.2.2, 4.3, 5.2-5.5, 7.1, 7.4, 7.7, and Articles 8, 9, 10 and 12. 

Article 9 — Indemnification, Defense and Insurance 

Indemnification and Defense. 
  

	9.1	 Except as set forth in Section 9.2 below, Licensee shall indemnify, defend and hold harmless DFCI
and its trustees, officers, medical and professional staff, employees, and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss or expense (including reasonable attorneys’
fees and expenses of litigation) incurred by or imposed upon the Indemnitees, or any one of them, in connection with any claims, suits, actions, demands or judgments (a) arising out of the design, production, manufacture, sale, use in commerce,
lease, or promotion by Licensee or by a Sublicensee, Affiliate or agent of Licensee, or any product, process or service relating to, or developed pursuant to, this Agreement or (b) arising out of any other activities of Licensee, its
Sublicensees, Affiliates, agents, or assigns, to be carried out pursuant to this Agreement. 

  

	9.2	 Licensee’s indemnification under 9.1 does not apply to any liability, damage, loss or expense to
the extent that it is attributable to (a) the negligence of the Indemnitees, or (b) the intentional wrongdoing or intentional misconduct of the Indemnitees. DFCI represents and warrants to Licensee that, to DFCI’s knowledge as of the
Effective Date, no claims of negligence have been asserted by any third party in respect of the Licensed Intellectual Property or its development. 

  
 17 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	9.3	 Licensee shall, at its own expense, provide attorneys reasonably acceptable to DFCI to defend against
any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought. 

 

	9.4	 If any such action is commenced or claim made or threatened against DFCI or other Indemnitees as to
which Licensee is obligated to indemnify it (them) or hold it (them) harmless, DFCI or the other Indemnitees shall promptly notify Licensee of such event. Licensee shall assume the defense of, and may settle, that part of any such claim or action
commenced or made against DFCI (or other Indemnitees) which relates to Licensee’s indemnification and Licensee may take such other steps as may be necessary to protect it. Licensee will not be liable to DFCI or other Indemnitees on account of
any settlement of any such claim or litigation affected without Licensee’s consent. The right of Licensee to assume the defense of any action is limited to that part of the action commenced against DFCI and/or Indemnitees that relates to
Licensee’s obligation of indemnification and holding harmless. 

  

	9.5	 Licensee shall require any Affiliates or Sublicensee(s) to indemnify, hold harmless and defend DFCI
under the same terms set forth in Sections 9.1 — 9.4. 

 Insurance. 

 

	9.6	 At such time as any product, process or service relating to, or developed pursuant to, this Agreement is
being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Licensee or by a Sublicensee, Affiliate or agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain policies of
commercial general liability insurance in amounts not less than [***] per incident and [***] annual aggregate and naming the Indemnitees as additional insureds. Such commercial general liability insurance must provide (a) product liability
coverage and (b) contractual liability coverage for Licensee’s indemnification under Sections 9.1 through 9.3 of this Agreement. If Licensee elects to self-insure all or part of the limits described above (including deductibles or
retentions which are in excess of [***] annual aggregate), such self-insurance program must be reasonably acceptable to the DFCI and the DFCI’s associated Risk Management Foundation. The minimum amounts of insurance coverage required under
these provisions may not be construed to create a limit of Licensee’s liability with respect to its indemnification obligation under Sections 9.1 through 9.3 of this Agreement. 

 

	9.7	 Licensee shall provide DFCI with written evidence of such insurance upon request of DFCI. Licensee shall
provide DFCI with written notice at least [***] ([***]) [***] prior to the cancellation, non-renewal or material change in such insurance; if Licensee does not obtain replacement insurance providing comparable
coverage within such [***] ([***]) [***] period, DFCI has the right to terminate this Agreement effective at the end of such [***] ([***]) [***] period upon written notice or additional waiting periods. 

  
 18 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	9.8	 Licensee shall maintain such comprehensive general liability insurance beyond the expiration or
termination of this Agreement during (a) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold (other than for the purpose of obtaining regulatory
approvals) by Licensee or by a Sublicensee, Affiliate or agent of Licensee and (b) a reasonable period after the period referred to in 9.8(a) above which in no event shall be less than [***] ([***]) [***]. 

 

	9.9	 License shall require any Affiliates or Sublicensee(s) to maintain insurance in favor of DFCI and the
Indemnitees under the same terms set forth in Sections 9.6 — 9.8. 

 Article 10 — Disclaimer of Warranties

  

	10.1	 DFCI MAKES NO WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF
MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK, SOFTWARE, NON-PUBLIC OR OTHER INFORMATION, OR BIOLOGICAL MATERIAL OR TANGIBLE RESEARCH PROPERTY, LICENSED OR
OTHERWISE PROVIDED TO LICENSEE HEREUNDER AND HEREBY DISCLAIMS THE SAME. 

  

	10.2	 DFCI DOES NOT WARRANT THE VALIDITY OF THE PATENT RIGHTS LICENSED HEREUNDER AND MAKES NO REPRESENTATION
WHATSOEVER WITH REGARD TO THE SCOPE OF THE LICENSED PATENT RIGHTS OR THAT SUCH PATENT RIGHTS MAY BE EXPLOITED BY LICENSEE, AFFILIATE OR SUBLICENSEE WITHOUT INFRINGING OTHER PATENTS. IF BIOLOGICAL MATERIALS ARE LICENSED HEREUNDER, DFCI MAKES NO
REPRESENTATION THAT SUCH MATERIALS OR THE METHODS USED IN MAKING OR USING SUCH MATERIALS ARE FREE FROM LIABILITY FOR PATENT INFRINGEMENT. 

  

	10.3	 THE LIABILITY OF DFCI, ITS AGENTS, OR ITS EMPLOYEES, WITH RESPECT TO ANY AND ALL SUITS, ACTIONS, LEGAL
PROCEEDINGS, CLAIMS, DEMANDS, DAMAGES, COSTS AND EXPENSE ARISING OUT OF THE PERFORMANCE OR NON PERFORMANCE OF ANY OBLIGATION UNDER THIS AGREEMENT WHETHER BASED ON CONTRACT, WARRANTY, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE), STRICT LIABILITY,
STATUTORY OR OTHERWISE SHALL BE LIMITED TO DIRECT, ACTUAL DAMAGES INCURRED AS A RESULT OF DFCI’s FAILURE TO PERFORM ITS OBLIGATIONS AS REQUIRED BY THIS AGREEMENT AND SHALL NOT EXCEED IN THE AGGREGATE A SUM EQUAL TO THE TOTAL AMOUNTS PAYABLE TO
DFCI UNDER THIS AGREEMENT. 

 Article 11 — Notices 

 

	11.1	 Notices to DFCI. Unless otherwise specified in this Agreement, reports, notices and other communications
from Licensee to DFCI as provided hereunder must be sent to: 

 Sr. Vice President for Research 

Dana-Farber Cancer Institute 
 44 Binney Street 

Boston, MA 02115 

  
 19 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 or other individuals or addresses as DFCI subsequently furnish by written notice to Licensee. 

A copy of the notice must also be sent to the attention of DFCI’s Vice President, Research and Technology Ventures, at the same address as provided
above. 
  

	11.2	 Notices to Licensee. Unless otherwise specified in this Agreement, reports, notices and other
communications from DFCI to Licensee as provided hereunder must be sent to: 

 [***] 

[***] 
 100 Capitola Drive, Suite 103 

Durham, NC 27713 
 with a copy (which shall not constitute
notice) to: 
 Womble Carlyle Sandridge & Rice, PLLC 

Attention: Deborah Hylton, Esq. 
 Post Office Box 13069 

Research Triangle Park, North Carolina 27709 
 or other
individuals or addresses as Licensee subsequently furnish by written notice to DFCI. 
 Article 12 — Dispute Resolution 

 

	12.1	 Negotiation between the Parties. The parties shall first attempt to resolve any controversy that arises
from this Agreement, or claim for breach of the Agreement, by good faith negotiations, first between their respective business development representatives and then, if necessary, between senior representatives for the parties, such as the Sr. Vice
President for Research or President of DFCI and the CEO or President of Licensee. 

  

	12.2	 Non-Binding Mediation. If the controversy or claim cannot be
settled through good faith negotiation between the parties, the parties agree first to try in good faith to settle their dispute by non-binding mediation under the Mediation Rules of the American Arbitration,
before resorting to arbitration, litigation or other dispute resolution procedure. 

 Article 13 — Independent
Contractor 
  

	13.1	 For the purpose of this Agreement and all services to be provided hereunder, both parties are and will
be deemed to be, independent contractors and not agents or employees of the other. Neither party has authority to make any statements, representations or commitments of any kind, or to take any action, that will be binding on the other party.

  
 20 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Article 14 — Severability 

 

	14.1	 If any one or more of the provisions of this Agreement is held to be invalid, illegal or unenforceable,
the validity, legality or enforceability of the remaining provisions of this Agreement will not in any way be affected or impaired thereby. 

Article 15 — Non-assignability 

 

	15.1	 Neither this Agreement nor any part of the Agreement is assignable by either party without the express
written consent of the other, which consent a party will not unreasonably withhold or delay. However, a Party may assign this Agreement without the other’s consent in conjunction with the sale of substantially all of its related business assets
or a merger, consolidation or reorganization to which it is a party, provided that such assignee, receiver, person or corporation shall, without delay, accept in writing the provisions of this Agreement and agree to become in all respects bound
thereby in the place and stead of Licensee or DFCI, as the case may be. Any attempted assignment in violation of this Article is void. 

Article 16 — Entire Agreement 
  

	16.1	 This instrument Agreement and all exhibits and schedules, which are incorporated by reference, contains
the entire agreement between the parties and supersedes and cancels all other agreements between the parties, including without limitation (a) that certain Option Agreement, dated January 23, 2004, by and between DFCI and Licensee, and
(b) that certain Term Sheet Proposal for License of Technology by and between DFCI and Licensee. No verbal agreement, conversation or representation between any officers, agents, or employees of the parties either before or after the execution
of this Agreement may affect or modify any of the terms or obligations herein contained. 

 Article 17 —–
Modifications in Writing 
  

	17.1	 No change, modification, extension, or waiver of this Agreement, or any of the provisions herein
contained is valid unless made in writing and signed by a duly authorized representative of each party. 

 Article 18
— Governing Law 
  

	18.1	 The validity and interpretation of this Agreement and the legal relations of the parties to it are
governed by the laws of the Commonwealth of Massachusetts without regard to any choice of law principle that would dictate the application of the law of another jurisdiction. 

Article 19 — Captions 
  

	19.1	 The captions are provided for convenience and are not to be used in construing this Agreement.

  
 21 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Article 20 — Construction 

 

	20.1	 The parties agree that they have participated equally in the formation of this Agreement and that the
language herein should not be presumptively construed against either of them. 

 Article 21 — Counterparts 

 

	21.1	 This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and
all of which, taken together, shall constitute one and the same instrument. 

 IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be executed by their duly authorized representatives as of the date first above written. 
  

									
	DANA-FARBER CANCER INSTITUTE, INC. (DFCI)	 		 	 CELLECTIVE THERAPEUTICS, INC.

(Licensee)

					
	By:	 	[***]	 		 	By:	 	[***]
					
	Title:	 	[***]	 		 	Title:	 	[***]
					
	Date:	 	                                      
          	 		 	Date:	 	                                     
           

  
 22 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 1: Patent Rights and Biological Materials 

[***] 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 

 
  

 CONFIDENTIAL 

September 8, 2005 
 [***] 

Vice President 
 Research and Technology Ventures 

Dana-Farber Cancer Institute, Inc. 
 44 Binney Street 

Boston, Massachusetts 02115 
 Dear [***]: 

This letter will serve to amend the Exclusive License Agreement between Cellective Therapeutics, Inc. (“Cellective”)
and Dana-Farber Cancer Institute, Inc. (“DFCI”), dated as of September 21, 2004 (the “Agreement”) and to clarify the intent of the parties regarding certain provisions set forth in the Agreement.

 1. Amendment to Section 2.1. Cellective and DFCI hereby agree to amend Section 2.1 of the Agreement to add a new
Section 2.1(b) as follows: 
  

	 	2.1(b)	 DFCI acknowledges that the Biological Materials have been transferred to Duke University and Dr. Thomas
Tedder. DFCI has authorized the direct release and transfer of the Biological Materials from the foregoing entities to Licensee, and the past or future transfer of the Biological Materials to Licensee is authorized in all respects by DFCI. Licensee
shall have the right to receive the Biological Materials from Duke University and Dr. Thomas Tedder upon its request and to use and transfer such Biological Materials to third parties in order to exercise its rights under this Agreement.

 2. Amendment to Section 2.5.3. Cellective and DFCI hereby agree to amend and restate
Section 2.5.3 of the Agreement in its entirety as follows: 
  

	 	2.5.3	 Copies of Sublicenses to DFCI. Licensee shall forward to DFCI a copy of any and all fully executed
sublicenses, including, without limitation, the identity of the Sublicensee; provided, that the Licensee may redact financial and other terms that are not relevant to Licensee’s obligations to DFCI hereunder. For avoidance of doubt, relevant
terms include but are not limited to those specified in section 2.5.2 of the Agreement. Such copy shall be postmarked within [***] days of the execution of the sublicense. Licensee shall also forward to DFCI annually a copy of the reports received
by Licensee from its Sublicensee during the preceding twelve (12) month period under the sublicenses as shall be pertinent to (1) its operations under the sublicense and (2) a royalty accounting under the sublicense agreement.

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 

 
  

 3. Amendment to Section 4.1. Cellective and DFCI hereby agree to amend
Section 4.1 of the Agreement by replacing the first sentence thereof with the following: 
 Within forty-five (45) days after
March 31, June 30, September 30 and December 31 of each year following First Commercial Sale in which this Agreement is in effect, Licensee shall deliver to DFCI full, true and accurate reports of its activities and those of its
Affiliates or Sublicensee(s), if any, relating to this Agreement during the preceding three month period. 
 4. Amendment to
Section 5.1.2. Cellective and DFCI hereby agree to amend the first sentence of Section 5.1.2 of the Agreement by deleting the phrase “Within [***] ([***]) after the Effective Date” and replacing it with the
phrase “On or before September 15, 2005.” 
 5. Limited Release and Acknowledgement. DFCI hereby waives and forever discharges
Cellective, its assigns, and successors, and any directors and officers of the foregoing (each, a “Released Entity”), from any claims that DFCI may have against any Released Entity arising out of, or relating to Cellective’s failure
to provide a development plan pursuant to the original Agreement. DFCI acknowledges receipt of a development plan, including a development and commercialization report, from Cellective on September 1, 2005. DFCI acknowledges and agrees, as of
the date that DFCI has executed this letter agreement, that (a) the Agreement is in full force and effect and has not been modified, changed, altered or amended in any respect except as provided in this letter agreement; and (b) to
DFCI’s best knowledge, Cellective is not in default in the performance or observance of any of its obligations under the Agreement, and there exists no event or condition which, with notice or the lapse of time or both, would constitute such a
default. 
 6. Amendment to Section 5.1.3(c). Cellective and DFCI hereby agree to amend and restate Section 5.1.3(c)
of the Agreement in its entirety as follows: 
  

	 	(c)	 First use in humans of the material described in subparagraph 5.1.3 (b) above on or before [***].

 7. Amendment to Section 5.5. Cellective and DFCI hereby agree to amend and restate Section 5.5 of
the Agreement in its entirety as follows: 
  

	 	5.5	 Publicity — Use of Name. Licensee, its Affiliates and Sublicensees are not permitted to use the
names of DFCI, its related entities or its employees, or any adaptations thereof, in any advertising, promotional or sales literature, without the prior written consent of DFCI in each case provided, however, that Licensee may (a) refer to
publications in the scientific literature by employees of DFCI, (b) state that a license from DFCI has been granted as provided in this Agreement, (c) refer 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 

 
  

	 	
to DFCI as a shareholder or licensor of Licensee to the extent required by applicable law, (d) refer to DFCI as a shareholder or licensor of Licensee in any securities report required by the
Securities and Exchange Commission, (e) disclose the identity of DFCI as a licensor to prospective or current third party contractors and collaborators of Licensee or (f) state that Dr. Thomas Tedder is a former employee of DFCI.

 8. Addition of Section 10.4. Cellective and DFCI hereby agree to add a new Section 10.4 of the Agreement as
follows: 
  

	 	10.4	 DFCI hereby represents and warrants to Licensee that, as of the signing date of this letter amendment and based
on its knowledge at that time: (a) DFCI is the sole and exclusive owner of, and has good and valid title to the Licensed Intellectual Property, free and clear of any encumbrance, lien, mortgage, charge, restriction or liability, whether
equitable or legal, that would conflict with or impair the rights granted to Licensee under this Agreement, with the exception of (i) the non-exclusive license granted to the United States government and
(ii) an exclusive license to a third party of US Patent [***]; (b) to DFCI’s knowledge, DFCI has properly obtained all rights to the Licensed Intellectual Property from the applicable inventors; and (c) DFCI will, within 30 days
provide Cellective with written documentation of DFCI’s election of title to Biological Materials from the United States government. 

9. Amendment to Schedule 1. Cellective and DFCI hereby agree toamend and restate Schedule 1 of the Agreement by replacing such schedule, in its
entirety, with the language designated on Appendix A to this letter agreement. 
 - remainder of page intentionally left blank - 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 

 
  

 The amendments set forth in this letter shall be effective upon signature hereof by both
parties. Other than as set forth in this letter, all of the terms and conditions of the Agreement shall continue in full force and effect. Please sign below and return to Cellective an executed copy of this letter to indicate your acceptance of the
terms contained herein. 
 Sincerely, 
 [***] 

[***] 
 [***] 

CELLECTIVE THERAPEUTICS, INC. 
 DANA-FARBER CANCER INSTITUTE,
INC. 
 ACCEPTED AND AGREED 
 By: [***] 

[***] 
 Title: Vice President, Research and
Technology Ventures 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 

 
  

 APPENDIX A 

The amended and restated Schedule 1 is set forth below. 

Schedule 1: Patent Rights and Biological Materials 

[***] 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]